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2 Summary 
Type  1  diabetes  (T1D)  is  a  chronic  T  cell-mediated  autoimmune 
disorder that results in the destruction of insulin-producing pancreatic 
ß  cells  leading  to  life-long  dependence  on  exogenous  insulin. 
Attraction, activation and transmigration of inflammatory cells to the 
site of ß-cell injury depend on two major molecular interactions. First, 
interactions  between  chemokines  and  their  receptors  expressed  on 
leukocytes result in the recruitment of circulating inflammatory cells to 
the site of injury. In this context, it has been demonstrated in various 
studies that the interaction of the chemokine CXCL10 with its receptor 
CXCR3  expressed  on  circulating  cells  plays  a  key  role  in  the 
development of T1D. Second, once arrived at the site of inflammation 
adhesion  molecules  promote  the  extravasation  of  arrested  cells 
through the endothelial cell layer to penetrate the site of injury. Here, 
the  junctional  adhesion  molecule  (JAM)  JAMﾖ–C  expressed  on 
endothelial cells is involved in the process of leukocyte diabedesis. It 
was  recently  demonstrated  that  blocking  of  JAM-C  efficiently 
attenuated cerulein-induced pancreatitis in mice. 
In my thesis I studied the influence of the CXCL10/CXCR3 interaction 
on the one hand, and of the adhesion molecule JAM-C on the other 
hand,  on  trafficking  and  transmigration  of  antigen-specific, 
autoaggressive T cells in the RIP-LCMV mouse model. RIP-LCMV mice 
express  the  glycoprotein  (GP)  or  the  nucleoprotein  (NP)  of  the 
lymphocytic  choriomeningitis  virus  (LCMV)  as  a  target  autoantigen 
specifically in the ß cells of the islets of Langerhans and turn diabetic 
after LCMV-infection. 
In  my  first  project  I  found  that  pharmacologic  blockade  of  CXCR3 
during development of virus-induced T1D results in a significant delay   8
but  not  in  an  abrogation  of  overt  disease.  However,  neither  the 
frequency  nor  the  migratory  properties  of  islet-specific  T  cells  was 
significantly changed during CXCR3 blockade. 
In  the  second  project  I  was  able  to  demonstrate  that  JAM-C  was 
upregulated around the islets in RIP-LCMV mice after LCMV infection 
and its expression correlated with islet infiltration and functional ß-cell 
impairment. Blockade with a neutralizing anti-JAM-C antibody slightly 
reduced  T1D  incidence,  whereas  overexpression  of  JAM-C  on 
endothelial cells did not accelerate virus-induced diabetes. 
In summary, our data suggest that both CXCR3 as well as JAM-C are 
involved  in  trafficking  and  transmigration  of  antigen-specific 
autoaggressive  T  cells  to  the  islets  of  Langerhans.  However,  the 
detection of only a moderate influence on the onset of clinical disease 
during CXCR3 or JAM-C blockade reflects the complex pathogenesis of 
T1D and indicates that several different inflammatory factors need to 
be neutralized in order to achieve a stable and persistent protection 
from disease.   9
3 Zusammenfassung 
Type  1  Diabetes  (T1D)  ist  eine  chronische  T  Zell-vermittelte 
Autoimmunerkrankung,  welcher  die  Zerstörung  der  ß  Zellen  der 
Langerhansﾒ’schen Inseln im Pankreas zugrunde liegt. Da die ß Zellen für 
die Insulinproduktion verantwortlich sind, führt dies zu einem absoluten 
Insulin-Mangel.  Es  wird  angenommen,  dass  die  Kombination  von 
genetischer  Veranlagung  und  Umweltfaktoren,  wie  Infektionen  durch 
Pathogene  oder  Xenobiotika,  die  Entstehung  von 
Autoimmunerkrankungen herbeiführen kann. Eine Entzündung in den ß 
Zellen, wird durch eine Rekrutierung von aktivierten Leukozyten, wie T 
Zellen, B Zellen und dentritische Zellen, ausgelöst. Für die Rekrutierung, 
Aktivierung  und  Transmigration  von  Leukozyten  sind  Interaktionen 
zwischen  Oberflächenrezeptoren  von  zirkulierenden  Leukozyten  und 
endothelialen  Entzündungsfaktoren  oder  Adhäsionsmolekülen 
verantwortlich.  Obschon  viel  über  die  Immunpathogenese  von  T1D 
bekannt ist, gibt es immer noch Unklarheiten mit welchen Mechanismen 
und  Interaktionen  die  antigen-spezifischen  T  Zellen  zu  den  ß  Zellen 
gelangen  und  wie  sie  durch  die  Endothelzellschicht  der  Inselzellen 
wandern. 
In meinem Projekt habe ich mich mit Hilfe des RIP-LCMV Maus-Modell 
für  T1D  mit  dem  Thema  der  gerichteten  Zellwanderung  und 
Extravasation detaillierter auseinandergesetzt. Unter der Kontrolle des 
Ratten-Insulinpromotors  (RIP)  exprimieren  transgene  RIP-LCMV-Mäuse 
das Glycoprotein (GP) oder das Nucleoprotein (NP) des lymphozytären 
Choriomeningitis Virus (LCMV) spezifisch in den ß Zellen. In den RIP-
LCMV Mäusen werden die Antigene (GP/NP) als körpereigen erkannt. 
Da die antigen-spezifischen Vorläufer T Zellen die GP oder NP Moleküle 
ﾂ‚tolerierenﾒ’ oder ﾂ‚ignorierenﾒ’ werden die ß Zellen nicht zerstört und die   10
transgenen Mäuse entwickeln keinen T1D. Eine Infektion von RIP-LCMV 
Mäusen mit LCMV hingegen verursacht eine Entzündung im Pankreas, 
die zu einer Anlockung und Aktivierung von Leukozyten und antigen-
spezifischen Vorläufer T Zellen führt. Die aktivierten LCMV-spezifischen 
T Zellen eliminieren nicht nur das Virus sondern beginnen auch die auf 
den  ß  Zellen  exprimierten  (viralen)  Zielantigene  anzugreifen.  Dieser 
autoimmune Vorgang verursacht die Zerstörung der ß Zellen und endet 
in T1D in nahezu 100% der infizierten RIP-LCMV-Mäuse. 
3.1  Blockierung von CXCR3 während T1D 
Die virusinduzierte Entzündung wird begleitet durch den Ausstoß von 
Chemokinen,  die  mit  Rezeptoren,  welche  von  Leukozyten  exprimiert 
werden,  interagieren  und  die  eine  gerichtete  Zellwanderung  zu  der 
beschädigten  (virusinfizierten)  Stelle  vermitteln.  In  diesem 
Zusammenhang  konnte  gezeigt  werden,  dass  das  Chemokin  CXCL10 
eine wesentliche Rolle in der Anlockung von autoaggressiven T Zellen 
zu  den  Langerhansﾒ’schen  Inseln  spielt.  In  unserem  RIP-LCMV  Maus-
Modell  beeinflusst  die  Neutralisation  oder  die  Überexprimierung  von 
CXCL10  die  Entwicklung  von  virusinduziertem  T1D  signifikant.  Der 
Rezeptor  CXCR3,  welcher  mit  CXCL10  interagiert,  wird  vorwiegend 
durch  die  aktivierten  TH1-typ  T  Zellen  exprimiert.  Es  konnte  gezeigt 
werden, dass in CXCR3-defizienten RIP-LCMV Mäusen die Entwicklung 
des T1D signifikant verzögert ist. Ferner wurden in einem Patienten mit 
T1D preproinsulin-spezifische CD8+ T Zell Klone gefunden, die CXCR3 
auf  ihrer  Oberfläche  exprimierten.  Diese  CD8+ T  Z e l l e n  k o n n t e n  
tatsächlich menschliche ß Zellen zerstören. 
Da in mehreren Studien nachgewiesen wurde, dass die Interaktion von 
CXCL10  mit  CXCR3  eine  wichtige  Rolle  in  Autoimmunerkrankungen 
spielt,  haben  wir  den  CXCR3  Rezeptor  mit  einem  Antagonist,   11
NIBR2130,  blockiert  und  dessen  Einfluss  auf  die  Entstehung  von 
virusinduziertem T1D im RIP-LCMV Maus-Modell untersucht. 
Die  pharmakologische  Blockade  von  CXCR3  während  der  Entwicklung 
des  T1D  führte  zu  einem  milden  aber  dennoch  signifikant 
verlangsamten Auftreten der Erkrankung. Die Blockade von CXCR3 war 
allerdings  nur  vorübergehend  wirksam.  Die  behandelten  Mäuse 
entwickelten  einen  T1D  sobald  die  Antagonisttherapie  abgesetzt 
wurde.  Die  Blockierung  von  CXCR3  hatte  keine  offensichtliche 
Auswirkung auf die Pathogenese des T1D. Weder die Funktion der ß 
Zellen  noch  die  Frequenz  und  das  Migrationsverhalten  der  Insel-
spezifischen aggressiven und regulatorsichen T Zellen wurden durch die 
Therapie signifikant beeinträchtigt. Unsere Resultate zeigen, dass eine 
Blockade eines wichtigen Chemokinrezeptors nur zu einem moderaten 
therapeutischen Effekt führt. In Anbetracht der gegebenen Komplexität 
der T1D Pathogenese einerseits und des Chemokin/Zytokin-Netzwerks 
andererseits,  müssten  wohl  mehrere  zentrale  Entzündungsfaktoren 
blockiert  werden,  um  eine  verbesserte  therapeutische  Wirkung  zu 
erreichen. 
3.2  Der Einfluss von JAM-C auf T1D 
Im  ersten  Teil  meiner  Arbeit  habe  ich  mich  mit  der  gerichteten 
Zellwanderung von Leukozyten auseinandergesetzt. Im zweiten Teil der 
Arbeit habe ich einen weiteren Schritt in der Immunpathogenese des 
T1D,  nämlich  die  Transmigration  der  zirkulierenden  Zellen  durch  die 
Endothelzellschicht,  analysiert.  Viele  verschiedene  Adhäsionsmoleküle 
(Selektine, Integrine und Immunglobulinsuperfamillien Proteine) werden 
durch Endothelzellen exprimiert und sind in das Rollen, die Aktivierung, 
die  Adhäsion,  und  dem  parazellulären  oder  transzellulären 
Durchwandern  von  Leukozyten  involviert.  Das  junktionale   12
Adhäsionsmolekül  C  (JAM-C)  ist  an  der parazellulären  Transmigration 
von  Leukozyten  beteiligt.  Es  konnte  gezeigt  werden,  dass  JAM-C  in 
verschiedenen inflammatorischen Krankheiten, wie Peritonitis, Arthritis 
oder Pankreatitis in Mäusen eine wichtige Rolle spielt. In einem Maus-
Modell für akute Pankreatitis ausgelöst durch die Injektion von Cerulein, 
konnte eine erhöhte JAM-C Expression im Pankreas beobachtet werden. 
Ferner  wurde  mit  Hilfe  eines  neutralisierenden  Antikörpers  JAM-C 
blockiert  und  dabei  konnte  die  Pankreatitis  reduziert  werden.  Die 
Immunpathogenese im Cerulein-Modell entspricht nicht exakt der des 
T1D  im  Menschen.  Dennoch  wurde  in  diesem  Maus-Modell 
nachgewiesen,  dass  die  Blockade  von  JAM-C  im  Pankreas  zu  einer 
reduzierten  Zellwanderung  und  Extravasation  von  Leukozyten  führte. 
Dies  hatte eine  Verminderung  der  lokalen  Entzündung  der  Inselzellen 
zur Folge. 
Aufgrund  dieser  Erkenntnisse  haben  wir  die  Rolle  von  JAM-C  im 
virusinduzierten T1D im RIP-LCMV Maus-Modell untersucht. Wir haben 
einerseits  JAM-C  mit  einer  Antikörperbehandlung  blockiert  und 
andererseits  JAM-C  auf  den  Endothelzellen  überexprimiert.  Nachdem 
RIP-LCMV Mäuse mit LCMV infiziert wurden, konnten wir eine erhöhte 
Expression von JAM-C beobachten. Diese Zunahme korrelierte gut mit 
dem Ausmaß der Leukozyteninfiltration und der ß Zell-Zerstörung. Die 
Neutralisation  von  JAM-C  resultierte  in  einem  leicht  reduzierten  und 
teilweise  revertierten  T1D.  Dennoch  konnte  nur  eine  moderate 
Auswirkung  auf  die  Frequenz  und  das  Migrationsverhalten  der  Insel-
spezifischen  T  Zellen  festgestellt  werden.  Die  Überexprimierung  von 
JAM-C  hatte  hingegen  keinen  Einfluss  auf  die  Entwicklung  der 
Krankheit. 
Unsere  Beobachtungen  zeigen,  dass  JAM-C  in  der  Pathogenese  des 
T1D eine eher untergeordnete Rolle zukommt. Die Funktion von JAM-C   13
wird  bei  einer  Blockade  möglicherweise  von  anderen 
Adhäsionsmolekülen  kompensiert.  Somit  ist  die  Infiltration  der 
Langerghansﾒ’schen  Inseln  durch  aggressive  T  Zellen  auch  bei  JAM-C 
Neutralisierung weiterhin gewährleistet.   14
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6 Introduction 
6.1  Overview of the immune system 
In  the  battle  against  pathogenic  invaders  such  as  viruses,  bacteria, 
fungi,  protozoa  and  parasites  many  defensive  mechanisms  have 
evolved,  which  finally  resulted  in  the  complex  immune  system  of 
vertebrates. 
The immune system can be divided into two distinct parts: the innate 
immune system, which reacts to pathogens in a non-antigen-specific 
manner, and the adaptive immune system, which is able to exert an 
antigen-specific response against pathogens. These two systems work 
together to generate an effective immune response. 
6.1.1  Innate immune system 
The  innate  immune  system  is  composed  of  a  number  of  barriers 
representing the first line of defense against infections. Innate immune 
responses include anatomic, physiologic, endocytic or phagocytic and 
inflammatory barriers. As anatomic barriers, the skin and the mucous 
membranes act as a first line of defense by preventing entry of most 
pathogens  into  the  body.  Physiological  barriers  include  body 
temperature,  low  pH,  and  chemical  mediators  such  as  lysozymes, 
interferons and the complement. The white blood cells, such as blood 
monocytes,  neutrophils,  natural  killer  cells  and  tissue  macrophages 
provide  the  phagocytotic  and  endocytotic  barriers,  by  engulfing  and 
digesting  microorganisms.  Moreover  in  response  to  microbes,  they 
secrete inflammatory factors, such as chemokines and cytokines that 
mediate  many  cellular  reactions  of  the  innate  immunity  and  can 
activate the adaptive immune system (1).   20
6.1.2  Adaptive immune system 
The adaptive immune system is characterized by its antigen specificity. 
It  can  be  divided  into  humoral  and  cell-mediated  responses.  B 
lymphocytes,  T  lymphocytes  and  antigen  presenting  cells  (APC)  are 
the primary cells involved. 
The  adaptive  immune  system  is  able  to  recognize  and  selectively 
respond  to  foreign  antigens.  Several  characteristics  of  the  adaptive 
immune system enable it to respond to a large variety of pathogens 
and toxins without attacking the organismﾒ’s own cells. One of those 
characteristics is the generation of recognition molecules that can be 
enormously diverse. Another one is the antigen-specificity that enables 
the immune system to distinguish subtle differences among antigens. 
Third, the development of immunological memory enables the immune 
system  to  respond  more  rapidly  and  more  effectively  to  a  second 
encounter with an antigen. The last characteristic is the self and non-
self  recognition  that  enables  the  immune  system  to  distinguish 
between  foreign  and  self  and  to  respond  only  to  non-self  antigens 
during  the  process  of  antigen  presentation.  An  aberrant  immune 
response  to  self-antigens  can  be  severe  and  can  lead  to  the 
development of autoimmune diseases (1). 
6.1.3  T Lymphocytes 
T cells originate from pluripotent hematopoietic stem cells in the bone 
marrow that migrate to the thymus, where they mature to different 
subsets of T cells. T cells recognize antigens with their T cell receptor 
(TCR)  only  when  the  antigen  is  associated  with  major 
histocompatibility complexes (MHCs) expressed by antigen presenting 
cells.  During  the  maturation  of  T  cells  within  the  thymus  the  cells 
undergo  distinct  phases  that  are  marked  by  the  status  of  T  cell   21
receptor gene rearrangement and the expression of T cell receptors. 
About five percent of the T cells rearrange the  and the  chain and 
develop into : CD3+ T cells. The majority of thymocytes rise to :ß T 
cells  that  have  to  pass  positive  and  negative  selection.  Only 
approximately  two  percent  of  all  these  thymocytes  survive  the 
selection processes and mature to immunocompetent T cells. During 
positive  selection  T  cells  that  interact  via  their  TCRs  with  self-MHC 
molecules  are  rescued  from  programmed  cell  death.  In  contrast,  in 
negative  selection  the  T  cells  that  bind  self-antigen  associated  with 
self-MHC molecules in a high-avidity manner are eliminated to maintain 
self-tolerance.  Once  T  cells  have  passed  the  two-step  selection 
process  so  called  central  tolerance  they  become  mature  T  cells 
expressing  either  CD4  or  CD8  co-receptors  and  can  enter  the 
periphery. 
Naïve  CD8+ T  c e l l s  i n t e r a c t  w i t h  p e p t i d e s  p r e s e n t e d  v i a  M H C  c l a s s  I 
molecules that are expressed on virtually all nucleated cells (2). Upon 
activation naïve CD8+ T cells differentiate into CD8+ cytotoxic T cells 
that can specifically lyse target cells by realising cytotoxic granules. In 
addition, they are able to produce interferon- (IFN-), tumor necrosis 
factor- ( T N F - )  and  lymphotoxin- ( L T - ).  IFN- i n h i b i t s  v i r a l  
replication, increases expression of MHC class I molecules and enhances 
the activity of macrophages (1). 
Naïve CD4+ T cells interact with peptide s presented via MHC class II 
molecules that are expressed on B cells, dendritic cells, macrophages, 
and  activated  T  cells  (2).  CD4+ T  c e l l s  s e c r e t e  l a r g e  q u a n t i t i e s  o f  
cytokines  in  response  to  antigen-specific  activation.  On  the  basis  of 
their  cytokine  production  and  their  function  they  can  be  subdivided 
into different subsets, such as T-helper type 1 (TH1), TH2, TH17 or T 
regulatory (Treg) cells.   22
TH1 cells develop in response to Interleukin 12 (IL-12) and IFN- and 
produce  IL-2  and  IFN-,  which  enhances  cellular  immunity,  activates 
macrophages  and  enables  them  to  destroy  intracellular 
microorganisms. They also can stimulate B cells producing antibodies 
and are important for autoimmunity and anti-tumor response. TH2 cells 
mature  in  response  to  IL-4  and  produce  IL-4,  IL-5,  IL-10  and  IL-13, 
which  enhance  humoral  immunity  by  activating  naïve  B  cells  and 
inducing  immunoglobulin  class  switching,  and  are  important  for 
extracellular defence. The recently discovered TH17 cells differentiate 
from naïve CD4+ T cells that have been activated in the presence of 
transforming  growth  factor-ß  (TGF-ß)  and  IL-6,  and  after 
differentiation they secrete IL-6, IL-17, IL-22, and TNF-. It also could 
be  shown  that  the  secretion  of  IL-23  by  APCs  maintains  TH17  cells 
survival.  TH17  cells  has  been  implicated  in  different  autoimmune 
diseases,  but  could  also  be  linked  to  providing  protection  in  certain 
infections (2, 3). Treg cells are Foxp3+ (transcription factor forkhead box 
P3+)  and  are  thought  to  participate  in  maintenance  of  peripheral 
tolerance and prevention of autoimmunity by suppressing other T cell 
responses. Two major groups of Treg cells are identified so far. The first 
group are naturally occurring CD4+CD25+ Treg cells that develop in the 
thymus  and  are  able  to  produce  TGF-ß  and  the  second  group 
differentiates  in  the  periphery  from  naïve  CD4+ T  c e l l s  a f t e r  T G F - ß ,  
retinoic acid and IL-2 induction (4). 
6.2  Autoimmunity 
Autoimmunity develops when central and/or  peripheral tolerance are 
overcome, tolerance to self-antigens is broken and autoreactive cells 
or antibodies are present. In autoimmune diseases those antibody and 
T cell responses become activated and cause clinical relevant damage.   23
The  development  of  autoimmune  diseases,  such  as  rheumatoid 
arthritis, multiple sclerosis, Graveﾒ’s disease, autoimmune hepatitis and 
T1D,  are  triggered  by  a  combination  of  genetic  predisposition  and 
environmental factors (1). 
6.2.1  Genetic susceptibility factors 
It  is  known  that  some  individuals  are  genetically  predisposed  to 
autoimmunity and that there are several genetic susceptibility factors 
that influence the development of autoimmune diseases. 
The most important genetic susceptibility factor is the MHC haplotype 
that is involved in the processes  of the central tolerance within the 
thymus where MHC alleles are involved in shaping the T cell repertoire 
(MHC  restriction).  In  addition,  MHC  haplotypes  are  also  important  in 
peripheral  tolerance  where  the  ability  of  T  cells  to  respond  to  a 
particular  antigen  depends  on  the  MHC  genotype  (5).  Another 
susceptibility factor is the autoimmune regulator (AIRE) that encodes a 
transcription factor that enables tissue-restricted self-antigens to be 
expressed by thymic epithelial cells. A defect in the gene AIRE leads to 
a breakdown of negative selection and to a severe autoimmune disease 
called autoimmune polyendocrinopathy candiasis ectodermal dystrophy 
(APECED) (1, 6). It could also be shown that cytolytic T lymphocyte-
associated antigen 4 (CTLA-4) and Protein tyrosine phosphatase, non-
receptor type 22 (PTPN22) are genetic susceptibility factors involved 
in  autoimmunity.  CTLA-4  is  a  key  negative  regulator  for  T  cell 
activation that limits the proliferative response of activated T cells to 
antigen whereas PTPN22 is involved in the negative control of T-cell 
activation and in T-cell development (7).   24
6.2.2  Environmental factors 
The discordance found in homozygotic twins and the observed overall 
north-south  geographical  gradient  of  autoimmune  diseases  in  the 
northern hemisphere suggest that environmental factors play a role in 
autoimmunity as well. Moreover the detection of higher prevalence of 
autoimmunity in more industrialized countries compared to countries 
with lower living standards (ﾓ“hygiene hypothesisﾔ”) emphases the idea 
of an involvement of environmental factors. In addition to drugs and 
toxins  perhaps  the  most  important  environmental  factors  in 
association with autoimmune diseases are microbial and viral infections. 
It  is  still  a  matter  of  debate  if  single  pathogen  infections  directly 
initiate  autoimmune  disease  or  rather  modulate  autoimmunity  in  an 
antigen-specific  and/or  antigen-nonspecific  (bystander  inflammation) 
manner.  In  concordance  with  the  hygiene  hypothesis  it  has  been 
demonstrated  that  infections  by  some  pathogens  can  protect  from 
autoimmunity (8). 
There  are a  lot  of  animal  models  available  in  which  the  influence  of 
microbial and viral infections on autoimmunity can be tested, but there 
are  difficulties  to  determine  a  direct  epidemiological  association 
between infections and various autoimmune disorders in human. One of 
the reasons might be that viral infections can be cleared years before 
the time of diagnosis (hit-and-run events). Further, infections might be 
latent  and  nearly  undetectable.  In  addition,  viral  infections  can  also 
ameliorate  disease  for  example  by  stimulation  of  Tregs o r  
hyperactivation of aggressive T cells (9). 
6.2.3  Virus-induced autoimmunity 
In  spite  of  central  and  peripheral  tolerance  mechanisms  some 
autoreactive B and T cells escape the tolerance mechanisms and are   25
present  in  all  individuals.  Even  though  autoantigens  of  these 
autoreactive  lymphocytes  are  present  they  are  not  able  to  initiate 
autoimmune  disease  by  their-selves.  Often  the  required  additional 
activation is provided by viral infections. Two possible mechanisms are 
proposed  for  such  virus-induced  activation  of  autoreactive 
lymphocytes  and  subsequent  autoimmunity.  First,  a  virus-induced 
inflammation might induce leukocyte activity and attraction to the side 
of  injury  in  an  antigen-independent  nonspecific  manner.  Second,  the 
production of cytokines and chemokines of bystander cells can lead to 
activation of autoreactive T cells. This bystander activation can further 
expand such low-affinity autoreactive cells that have escaped negative 
selection or can awake anergic autoaggressive T cells (9, 10). 
In the other pathway virus can break self-tolerance by sharing similar 
epitopes with the host that leads to a cross-reactive immune response. 
This  mechanism  is  called  molecular  mimicry  (11).  Two  of  the  best 
examples of molecular mimicry in autoimmune diseases are rheumatic 
fever and Guillain-Barré syndrome. In rheumatic fever individuals can 
develop an autoimmune disease due to infection with Streptococcus 
pyogenes,  where  its  dominant  epitope  shares  structural  similarity  to 
the  lysoganglioside  of  the  host.  This  cross-reactivity  can  lead  to 
antibody-mediated autoimmunity (12). In Guillain-Barré syndrome the 
infection with Campylobacter jejuni that shares a structural homology 
of the lipo-oligo-saccharide with peripheral nerve GM1 ganglioside can 
cause autoimmune disorders affecting the peripheral nervous system 
(13). In both cases convincing mouse models that support the role of 
molecular mimicry have been established. In the RIP-LCMV model for 
T1D,  (see  chapter:  The  RIP-LCMV  Model  for  T1D)  molecular  identity 
seems to be required to induce autoimmune disease. Briefly, infection 
of  transgenic  RIP-LCMV  mice,  which  express  LCMV-proteins  in  the   26
pancreas, with LCMV itself (molecular identity) results in autoimmunity 
and the development of type 1 diabetes. In contrast, infection of RIP-
LCMV mice with Pichinde virus that shares an epitope that is cross-
reactive  with  a  LCMV  protein  epitope  (molecular  mimicry)  is  not 
sufficient to establish autoimmune disease (14). Overall, the evidence 
that molecular mimicry alone can induce autoimmune diseases remains 
controversial  and  it  may  need  several  sequential  or  coinciding 
environmental challenges to induce autoimmunity. 
In  summary,  any  genetic  susceptible  individual  might  be  repeatedly 
exposed to infections without developing autoimmunity. But induction 
of disease might be possible if bystander activation, molecular mimicry 
as well as virus persistence coincide and the threshold for autoimmune 
diseases is exceeded (ﾓ“fertile fieldﾔ” hypothesis) (9, 15). A dynamic and 
complex  interaction  between  genetic  and  environmental  factors  is 
likely  to  be  involved  in  the  initiation  and  abrogation  of  autoimmune 
disease. 
6.3  Diabetes overview 
Diabetes  mellitus ( D M )  i s  a  g r ou p  o f d i so r d e r s o f m u l t i p l e  e t i o l o g i e s  
characterized  by  chronic  hyperglycemia  with  disturbances  of 
carbohydrate,  fat  and  protein  metabolism  resulting  from  defects  in 
insulin secretion, insulin action, or both. 
Based upon etiology, diabetes can be divided into four main groups. In 
T1D  the  absolute  insulin  deficiency  occurs  due  to  an  autoimmune-
associated  destruction  specifically  of  the  insulin-producing  ß  cells  in 
the islets of Langerhans, whereas in type 2 diabetes the relative insulin 
deficiency  happens  due  to  decreased  effect  of  insulin  in  the  target 
tissues or due to secretory defects of insulin with or without insulin 
resistance. In the gestational diabetes the glucose intolerance results   27
in  hyperglycemia  of  variable  severity  with  onset  or  first  recognition 
during pregnancy. Finally the forth group includes other specific types 
of diabetes such as specific genetic defects of ß cell function, diseases 
of the exocrine pancreas, endocrinopathies and infections (16). 
6.3.1  Anatomy and function of the pancreas 
The pancreas is a gland organ in the digestive and endocrine system of 
vertebrates with lobular architecture and it can be divided into three 
parts, the head, the body and the tail. 
The pancreas is located across the back of the abdomen, behind the 
stomach. The head of the pancreas is attached to the small intestine 
whereas the tail of the organ extends slightly upward and ends near 
the spleen. 
The  exocrine  tissue  within  the  pancreas  is  considered  to  be  a 
compound gland that produces digestive enzymes and an alkaline fluid 
(called  pancreatic  juice),  and  secretes  them  through  a  system  of 
exocrine ducts into the small intestine. The islet cells of Langerhans 
that are crisscrossed by a dense network of capillaries compose the 
endocrine  part  of  the  pancreas  and  are  scattered  throughout  the 
pancreas  (17).  Discovered  1869  by  a  pathologic  anatomist  Paul 
Langerhans,  the  islets  of  Langerhans  constitute  about  1-2%  of  the 
mass of a human pancreas and are most numerous in the head (18). 
There are four main cell types in the islets that can be classified by 
their secretion of hormones in the bloodstream. Mostly prominent are 
the  ß  cells  that  secrete  insulin  and  thus  lower  the  glucose  levels. 
Contrary to ß cells,  cells secrete glucagon that induces the release 
of  glucose  into  the  blood  stream  resulting  in  an  increase  of  blood 
glucose  levels.   c e l l s  p r o d u c e  s o m a t o s t a t i n  a n d  i n h i b i t  i n s u l i n ,  
glucagon,  and  pancreatic  polypeptide (PP)  secretion.  Lately,  PP  cells   28
are  a  very  few  numbers  that  secrete  pancreatic  polypeptide,  which 
inhibits intestinal motility, pancreatic exocrine and bile secretion and 
stimulates gastric leader cells. Human islets show different architecture 
compared  with  rodent  islets.  In  human,  ß,  ,  ,  and  PP  cells  are 
distributed  throughout  the  whole  islets  whereas  in  rodents,  ß  cells 
form the core of the islets and , , and PP cells form the mantle of 
the islets (17, 19). 
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Figure 1: Composition of the pancreas. 
(A) The pancreas is divided into three parts: the head attached to the small intestine, the 
body, and the tail that ends near the spleen. The islet cells are distributed throughout the 
pancreas, and are most frequent in the head. Islets are composed of ß, ,  and PP cells. (B) 
An immunohistological staining of insulin of a murine islet cell and a fresh isolated islet  cell 
after 7 days of culturing. (Adapted from Encyclopaedia Britannica, Inc 2003) 
6.3.2  Type 1 diabetes 
Type 1 diabetes mellitus (T1D) occurs in 5% to 10% of all cases of 
diabetes,  affects  primarily  children  and  results  from  T  cell-mediated 
destruction  of  pancreatic  ß  cells.  As  also  observed  for  other 
autoimmune diseases a north to south decrease in T1D incidence has 
been reported. For example the incidence seen in Finland (40 cases per 
100,000/year) is extremely high compared with extremely low rates in   29
Venezuela (0.1 cases per 100,000/year) (20). However, the incidence 
of  T1D  is  also  highly  variable  among  different  ethnic  and  racial 
populations  as  in  Estonia  that  borders  Finland  has  only an  incidence 
rate of about one quarter of its neighbor. Moreover, some ﾑ‘hot-spotsﾒ’ 
in warm climates such as Sardinia with almost as high rate as in Finland 
have  also  been  reported  (21).  These  observations  indicate  that  not 
only geographic position plays a role but probably the combination of 
genes  and  environment  (see  chapters:  Genetic  susceptibility  factors 
and Environmental factors). 
As  mentioned  above,  T1D  is  a  multifactoral  autoimmune  disease 
thought to originate from the combination of susceptibility genes with 
environmental  factors.  Susceptibility  and  protection  from  T1D  is 
associated with the major histocompatibility complex (MHC) HLA class 
II DR and DQ molecules. The HLA DR3/4-DQ8 heterozygous genotype 
is  the  genotype  associated  with  the  highest  risk  for  T1D.  Whereas 
DQB1*0602  are  associated  with  protection  from  T1D  in  multiple 
populations (22). Further non-HLA loci genes are associated with T1D 
susceptibility. For instance, the insulin gene (VNTR), where short forms 
of  a  variable  number  tandem  repeat  in  the  insulin  promoter  are 
associated  with  susceptibility  to  disease,  longer  forms  provide 
protective  effects.  In  addition,  PTPN22  as  well  as  CTLA-4  are  also 
reported to be implicated in T1D susceptibility (23). 
Besides climatic influences viral infection, early infant diet and toxins 
also  serve  as  modifiers  of  disease  pathogenesis.  Viruses,  such  as 
rubella, coxackie virus and enteroviruses have been reported to play a 
role in etiology of T1D. It could be shown that patients suffering from 
T1D  harbored  higher  levels  of  coxsackievirus-specific  antibodies 
compared  with  control  population.  Moreover  infection  of  coxsakie  B 
virus, isolated from diabetic patient, enhanced T1D onset in nonobese   30
diabetic  (NOD)  mice  (24).  Not  only  viruses  have  been  reported  to 
modulate  the  course  of  T1D  there  is  also  a  report  existing  that 
maternal  intake  of  Vitamin  D  in  food  during  pregnancy  can  protect 
against islet autoimmunity in offspring (25). It is supposed that active 
vitamin  D3  modifies  dendritic  cell  action  and  T  cell  differentiation 
following shifting the balance to regulatory T cells. 
The detection of autoantibodies against islet antigens in the blood is 
highly  predictive  of  the  development  of  T1D.  The  three  principal 
autoantibodies react with glutamic acid decarpoxylase (GAD65) (26), 
insulin (27) and insulinoma antigen-2 (IA-2) (28) and can be present in 
some  individuals  for  decades  prior  until  up  to  80%  of  ß  cells  are 
destroyed and T1D develops (29). 
Insulitis in human samples contained CD8+ and CD4+ T cells, B cells and 
macrophages, with a predominance of CD8+ T cells (29). It is proposed 
that  development  of  islet  autoimmunity  primary  requires  genetic 
predisposition and a critical repertoire of autoreactive T cells against 
islet antigens. Furthermore, a local event such as viral infection or APC 
dysfunction could via molecular mimicry or bystander effects activate 
such  autoreactive  T  cells  and  afford  their  migration  to  the  target 
organ. Following secretion of various cytokines such as IL-1ß, TNF- 
and nitric oxide as well as cytotoxic T cells finally cause the destruction 
of ß cells leading to the outcome of disease (2). 
There  are  several  prevention  strategies  to  enhance  regulatory 
responses  and  dampen  aggressive  anti-islet  activities.  As  an  antigen 
non-specific intervention the T cell depletion with an anti-CD3 antibody 
could be shown to have encouraging outcome. In two different phase 
I/II intervention trials with anti-CD3 antibodies a remission or a reduced 
insulin  requirement  out  to  18  months  could  be  reached  (30,  31). 
Moreover, an islet-antigen specific DNA vaccine that induces Treg cells   31
has  demonstrated  striking  efficacy  in  recent-onset  diabetes  in  NOD 
mice  (32).  However,  an  even  more  promising  attempt  would  be  to 
combine the non-specific and antigen-specific intervention mentioned 
above. Indeed there are in vivo studies showing success in prolonging 
the onset of T1D in mice using a so called combination-therapy (33). 
However,  it  will  need  more  time  and  research  to  establish  such  a 
combination-therapy in humans and to ensure that there are no side 
effects. Besides different prevention strategies islet transplantation is 
one  of  the  most  promising  treatments  for  diabetes  so  far.  The 
landmark for islet transplantation was done in 1999 where 7 patients 
underwent  isolated  islet  transplantation  and  achieved  insulin 
independence for at least one year. The treatment protocol used was a 
corticosteroid-free  immunosuppression  regimen,  known  as  Edmonton 
protocol (34). However, many of the patients required more than one 
infusion of islets from two donor pancreata. One of the most serious 
problems is the impairment and loss of the islet function over time. 
Infused islet cells are new targets for the autoaggressive processes of 
the  autoimmune  disease.  After  islet  transplantation  hypoglycemic 
episodes can be avoided but T1D is still not cured (35). Anyway, until 
now  the  best  way  to  keep  the  disease  under  control  is  a  livelong 
controlled injection of insulin (32). 
6.4  Mouse models for T1D 
The  two  most  frequently  used  mouse  models  for  T1D  are  the 
spontaneous  nonobese  diabetic  (NOD)  mouse  that  was  discovered 
1980 (36) and the inducible RIP-LCMV mouse model established in two 
different  laboratories  by  Michael  Oldstone  (37)  and  Hans 
Hengartner/Rolf Zinkernagel in 1991 (38).   32
6.4.1  Classification  and  morphology  of  the 
lymphocytic choriomeningitis virus 
Lymphocytic choriomeningitis virus (LCMV) is a member of the genus 
Arenavirus  in  the  family  of  Arenaviridae  and  is  normally  carried  by 
rodents.  The  LCMV  genome  consists  of  two  negative-sense  single-
stranded  RNA  segments,  a  short  (S)  and  large  (L)  segment,  with 
approximate size of 3.4 and 7.2 kb, respectively (39, 40). Each RNA 
species  contains  two  genes  encoded  in  opposite  orientation 
(ambisensed RNA). The S RNA encodes for the two major structural 
proteins of LCMV, namely the nucleoprotein NP and the glycoprotein 
precursor (GP-C). The two virion glycoproteins GP-1 and GP-2 derive 
by posttranslational cleavage of GP-C. Tetramers of GP-1 and GP-2 are 
present on the surface of the virion and mediate virus interaction with 
the  host  cell  surface  receptors.  The  NP,  the  most  abundant  viral 
protein  in  virus-infected  cells,  is  present  within  the  virion  and 
encapsulates  viral  RNA.  The  L  RNA  segment  encodes  for  the  non-
glycosylated L protein, which is presumably the viral RNA dependent 
RNA polymerase and for the RING finger Protein (Z) (40, 41). 
LCMV is a model virus often used in research of viral immunity. One of 
its advantages is that it induces a tremendous (i.e. easily measured) 
immune response. The LCMV infection of mice leads to the generation 
of a strong cytotoxic T lymphocyte (CTL) response and therefore the 
immune  response  peaks  6  to  8  days  after  infection.  That  makes  it 
relatively  easy  to  detect  individual  components  of  the  immune 
response (42, 43).   33
6.4.2  The RIP-LCMV Model for T1D 
As  mentioned  previously  (see  chapter:  Mouse  models  for  T1D)  two 
different  groups  created  separate  transgenic  mouse  lines  in  which 
either the glycoprotein (GP) or the nucleoprotein (NP) are expressed as 
defined target antigen in pancreatic ß cells under the control of the rat 
insulin promoter (RIP) (37, 38). In these mice both target antigens are 
considered  as  ﾑ‘selfﾒ’  and  the  mice  are  ignorant  or  tolerant  to  these 
antigens  (Figure  2.1).  Therefore,  these  RIP-LCMV  mice  do  not  show 
islet-cell infiltration, ß cell dysfunction, hyperglycaemia, or spontaneous 
activation  of  autoreactive  (anti-LCMV)  lymphocytes.  However,  LCMV 
infection triggers autoimmune diabetes within 10-14 days in the RIP-
LCMV-GP mice and 1-6 months in the RIP-LCMV-NP mice in a two-step 
manner.  First,  upon  infection  of  the  pancreas  the  innate  immune 
system  is  initiated,  resident  macrophages  or  dendritic  cells  are 
activated and release pro-inflammatory cytokines, such as IFN-, TNF-
, and IL-1. Moreover, activated ß cells and endothelial cells release 
chemokines,  such  as  CXCL10,  resulting  in  an  attraction  of activated 
lymphocytes  as  well  as  the  first  autoaggressive  T  cells  in  an  non-
specific manner (Figure 2.2). In a second stage, over time an antigen-
specific  immune  response  evolves  and  attacks  target  antigens 
expressed by virus and ß cells. After clearance of the virus the only 
viral antigen available is expressed by ß cells. Therefore, some LCMV-
specific T cells kill ß cells in a perforin dependent manner leading to an 
increase in islet- as well as LCMV-antigen presentations by professional 
APCs. Finally, this increase results in further expansion and proliferation 
of  autoaggressive  T  cells  and  together  with  the  bystander 
inflammation the destruction of most ß cells and overt diabetes follows 
(Figure 2.3-4).   34
As  mentioned  earlier  (see  chapter:  Autoimmunity),  in  these  mouse 
models molecular identity rather than molecular mimicry is responsible 
for the induction of T1D (11, 44, 45). 
Anyway, in this RIP-LCMV mouse model the onset of diabetes depends 
on  the  autoreactive  CD8+ a n d  C D 4 + T  c e l l s .  A s  m e n t i o n e d  a b o v e ,  
LCMV-infection  of  RIP-LCMV-GP  and  RIP-LCMV-NP  mice  results  in  a 
different diabetes onset. It is believed that this difference is due to the 
distinct  expression  pattern  of  the  transgene.  The  RIP-LCMV-GP  mice 
(fast-onset) express the LCMV-GP transgene exclusively in the ß cells 
and  not  in  the  thymus.  Therefore,  GP-specific  CD8+ T  c e l l s  a r e  n o t  
negatively selected in the thymus and after LCMV infection the high 
systemic numbers of autoaggressive CD8+ T  cells are able to induce 
diabetes without the help of CD4+ T cells. In contrast, in the RIP-LCMV-
NP  mice  (slow-onset)  the  LCMV-NP  transgene  is  expressed  in  the  ß 
cells as well as in the thymus resulting in the deletion of high-affinity 
NP-specific  T  cells.  The  low-affinity  NP-specific  CD8+ T  c e l l s  i n  t h e  
periphery are not sufficient to induce diabetes after LCMV infection. 
For this reason they need the assistance of CD4+ T cells to induce T1D 
(46). 
Hence, the RIP-LCMV mouse model is an attractive tool to study the 
mechanisms  of  T1D.  Its  advantages  compared  with  other  mouse 
models, such as the NOD mice, are the clearly defined initiation point 
(LCMV-infection) that enables to study the precise kinetics of disease, 
the  organ  (islet)  restricted  disease  and  the  presence  of  well-
characterised  target  antigens  (GP,  NP).  Moreover,  there  are  tools 
available  to  easily  visualize  these  target  antigens  by  MHC  class  I-
peptide  tetramers  in  flow  cytometry  or  directly  on  quick  frozen 
sections (47).   35
 
Figure 2: RIP-LCMV mouse model. 
(1)  Transgenic  RIP-LCMV  mice  are  tolerant  or  ignorant  to  their  glycoprotein  (GP)  or 
nucleoprotein (NP) of lymphocytic choriomeningitis virus (LCMV) expressed by their ß cells. 
(2)  LCMV  infection  causes  local  non-specific  inflammation  and  chemokines  and  cytokines 
attract and activate leukocytes as well as LCMV-specific precursor lymphocytes by bystander 
activation. (3) Specific anti-LCMV lymphocytes are activated and expanded reacting against 
the target antigen GP or NP expressed by the virus or the ß cells. After virus elimination the ß 
cells express the only remaining target antigen. (4) Finally, this results in increased destruction 
of ß cells and subsequently overt diabetes. (Adapted from Urs Christen) 
6.5  Chemokines 
6.5.1  Chemokines overview 
Chemokines and cytokines have been implicated in several autoimmune 
diseases,  homeostasis,  development,  host  defense  mechanisms,  and 
pathogen  infections  and  can  have  both  beneficial  and  exacerbating 
effects. In microbial or viral infections chemokines and cytokines play a 
pivotal role in attraction and activation of leukocytes with the aim of 
controlling  the  invading  pathogen.  Mainly  resident  macrophages  or 
endothelial cells release chemokines upon activation by cytokines, like 
IFN- and TNF-. The chemokines released coordinate both the timing 
and location of invading cell populations as well as the composition of 
these infiltrating immune competent cells (44, 45).   36
Chemokines are small molecules (~ 8-14 kDa) divided into two major 
subfamilies on the basis of the arrangement of the N-terminal cysteine 
residues,  CC  chemokines  with  two  adjacent  cysteines  and  CXC 
chemokines  with  the  equivalent  two  cysteine  residues  that  are 
separated by a single amino acid. Chemokines interact with a subset of 
G  protein-coupled  seven-membrane-spanning  receptors  that  are 
expressed by their target cells, such as a variety of leukocytes (45, 
48, 49). 
6.5.2  The role of cytokines in T1D 
In  T1D,  the  immune  response  is  characterized  by  type  1  cytokines 
(IFN- and IL-2) that are thought to enhance autoimmune processes 
and have mainly pro-diabetic influences, type 2 cytokines (IL-4, IL-5, 
IL-10, and IL-13) and TGF-ß secreted by CD4+CD25+ Treg cells that have 
supposable  more  regulatory  functions  (44,  50).  Although  a  recent 
study has shown an upregulation of TH17 immunity in peripheral blood 
T cells from children with T1D (51), to date is not entirely clear how 
TH17 cytokines (IL-17, and IL-22) are involved in T1D (see chapter: T 
Lymphocytes). 
Several  studies  investigated  the  role  of  the  two  major  pro-
inflammatory cytokines IFN- and TNF- in mouse models for T1D. In 
the RIP-LCMV transgenic IFN--deficient mice the incidence of disease 
was  drastically  reduced  (52),  whereas  TNF- p l a y s  a  d u a l  r o l e  
depending on the time of expression. The early expression of TNF- in 
the RIP-LCMV mouse model led to enhancement of the frequencies of 
diabetic mice, whereas late expression reversed the auto-destructive 
process (53).     37
6.5.3  The role of CXCL10 and CXCR3 in T1D 
The CXCR3 chemokine receptor is the only receptor known so far that 
binds the three chemokines CXCL9 (MIG or monokine induced by IFN-), 
CXCL10 (IP-10 or IFN--inducible protein 10 of 10 kDa), and CXCL11 
(I-TAC  or  interferon-inducible  T  cell  alpha  chemoattractant).  Upon 
stimulation  with  TNF- a n d  I F N -  t h e  C X C R 3  l i g a n d s  a r e  m a i n l y  
expressed  by  macrophages,  fibroblasts,  endothelial  cells,  and 
keratinocytes but are also expressed by normal T cells, thymocytes, 
and activated T cell hybridomas (50, 54). 
CXCL10 is thought to be involved in various inflammatory pathologies 
by attracting leukocytes to the sites of infection or injury. Moreover, 
CXCL10 plays a role in inhibition of angiogenesis, wound healing, and 
antiviral response. CXCL10 is highly expressed early after infection with 
several viruses, such as HIV, LCMV, adenovirus, and mouse hepatitis 
virus  (55,  56).  Due  to  their  unspecific  paracrine  nature  CXCR3 
chemokines activate T cells as well as autoreactive T cells (ﾑ‘bystander 
activationﾒ’)  and  thereby  direct  the  anti-viral  response  towards  the 
more  aggressive  TH1-type  T  cell  dominance  that  can  lead  to  an 
autoaggressive immune defense and finally might end in autoimmune 
disease. In fact, several evidences suggest a pivotal role of CXCL10 in 
the course of T1D in the RIP-LCMV mouse model. First, neutralization 
of  CXCL10,  but  not  CXCL9,  resulted  in  decreased  cellular  infiltration 
and  abrogated  T1D  by  inhibiting  the  expansion  and  migration  of 
antigen-specific T cells into the islets (56). Second, in both the RIP-
LCMV  and  NOD  mice,  expression  of  CXCL10  during  the  ongoing 
autoaggressive  immune  response,  outside  the  pancreas  attracted 
antigen-specific cells out of the pancreas and abrogated disease. This 
inflammation outside the pancreas was achieved by an infection of a   38
virus that predominantly accumulates in the pancreatic draining lymph 
nodes (PDLN). The autoaggressive cells then migrated along a CXCL10 
gradient  to  the  PDLN  and  once  arrived  the  hyper-activated  cells 
underwent apoptosis (14). Third, transgenic mice that express CXCL10 
specifically  in  the  ß  cells  of  Langerhans  have  spontaneous  islet 
infiltration  but  do  not  develop  spontaneous  diabetes  indicating  that 
this  bystander  activation  is  not  sufficient  to  induce  disease. 
Nevertheless, if these mice are crossed with RIP-LCMV mice the islet-
specific CXCL10 expression lead to an enhancement of antigen-specific 
T cell migration to the pancreas and to an acceleration of T1D after 
LCMV-infection (57). 
As mentioned above, the receptor known for CXCL10 is CXCR3, which 
is a G protein-coupled seven-membrane-spanning glycoprotein that is 
internalized upon activation. This internalization leads to calcium influx 
and intracellular activation of signaling cascade that includes kinases 
and  finally  often  cytoskeleton  rearrangement  and  cell  movement. 
CXCR3  is  expressed  by  natural  killer  cells,  B  cells,  plasmacytoid  and 
myeloid dendritic cells, and predominantly expressed by activated TH1-
type  T  cells  (58,  59).  CXCR3-deficient  mice  crossed  with  RIP-LCMV 
mice showed a significant delay but no abrogation of the development 
of  virus-induced  diabetes  (60).  In  another  study  neither  CXCR3-
deficient  mice  nor  a  pharmacologic  blockade  of  CXCR3  with  an 
antagonist in rats had an effect on cardiac allograft survival (61).   39
6.6  Adhesion molecules 
6.6.1  Rolling,  adhesion  and  transmigration  -  the 
families of adhesion molecules 
Leukocyte extravasation from the blood to site of injury or infection is 
essential in the development of an inflammatory response. This event 
is strictly controlled by a multistep action of chemokines and adhesion 
molecules (62, 63). 
In  the  leukocyte  adhesion  cascade  that  includes  tethering,  rolling, 
activation  and  arrest,  adhesion  strengthening,  crawling  and  finally 
paracellular or transcellular migration is mediated by a lot of different 
cell adhesion molecules (CAMs) such as selectins, integrins, cadherins 
and cell adhesion molecules of the immunoglobulin superfamily (Figure 
3) (64-66): 
6.6.1.1  Selectins (P-, E- or L-selectin) 
Selectins  are  a  family  of  heterophilic  CAMs  that  bind  glycosylated 
ligands such as P-selectin glycoprotein ligand 1 (PSGL1) and are the 
adhesion  molecules  expressed  on  inflamed  endothelial  cells  that 
interact with a leukocyte during the rolling process. Under conditions 
of  blood  flow  they  are  able  to  capture  leukocytes  in  a  high 
dissociation/association  rate  allowing  the  leukocytes  to  role  and  to 
sense chemoattractants on the endothelial wall (Figure 3). L-selectin is 
expressed  by  most  leukocytes  whereas  E-  and  P-selectins  are 
synthesized  by  inflamed  endothelial  cells.  In  addition,  P-selectin  can 
also be expressed by activated platelets (64, 66, 67). After treatment 
of  NOD  mice  with  an  antibody  neutralizing  L-selectin  insulitis  was 
reduced and the severity of T1D was decreased (68). However, if the   40
mice  were  treated  during  an  ongoing  diabetogenic  response,  the 
blockade of L-selectin could only marginally delay the disease (69). 
6.6.1.2  Integrins (LFA-1, Mac-1, VLA-4) 
Integrins  are  heterodimers  of   a n d  ß  s u b u n i t s  t h a t  a r e  p a r t i c u l a r l y  
expressed  by  leukocytes  and  mediate  leukocyte  adherence  to  the 
vascular endothelium or other cell-cell interactions. During rolling, after 
leukocytes  have  bound  to  the  chemokines  present  on  endothelial 
surfaces,  the  constitutively  expressed  integrins  get  activated  and 
improve their affinity and/or avidity for their ligands expressed on the 
endothelium.  These  processes  finally  lead  to  rolling  arrest  and  firm 
adhesion (Figure 3) (1, 64, 66). The importance of integrins in T1D is 
illustrated  by  an  adoptive  transfer  experiment  in  NOD  mice,  where 
neutralization of the integrin VLA-4 (very late antigen 4) resulted in a 
complete reduction of T1D (68).  
6.6.1.3  Immunoglobulin  (Ig)  superfamily  (ICAMs,  VCAM-1, 
PECAM-1, JAMs) 
The  Ig  superfamily  CAMs  (IgSF  CAMs)  are  calcium-independent 
transmembrane  glycoproteins  that  are  either  homophilic  or 
heterophilic.  Member  of  the  IgSF  CAMs  include  the  intercellular 
adhesion molecules (ICAMs), vascular-cell adhesion molecule 1 (VCAM-
1),  platelet-endothelial-cell  adhesion  molecule  (PECAM-1),  neural-cell 
adhesion molecule (NCAM) and junctional adhesion molecules (JAMs). 
Most  Ig  superfamily  CAMs  play  a  role  in  paracellular  transmigration 
whereas ICAM-1 is involved in transcellular migration as well. 
ICAM-1 is constitutively expressed in low concentrations on endothelial 
cells and on several leukocytes. However, upon inflammation ICAM-1 is 
highly  upregulated  on  endothelial  cells  only.  ICAM-1  can  bind  LFA-1 
(leukocyte  function-associated  antigen1)  and  MAC-1  (Macrophage-1   41
antigen) of activated leukocytes and plays an important role in rolling 
arrest and firm adhesion (Figure 3) (63, 70). 
VCAM-1  is  mainly  expressed  on  vascular  endothelium  and  only  after 
cytokine stimulation of endothelial cells. Like ICAM-1 it also mediates 
adhesion  of  leukocytes  to  the  vascular  endothelium  (67,  70).  In  an 
adoptive  transfer  model  of  diabetes  in  NOD  mice  neutralization  of 
ICAM-1  had  only  a  marginal  effect  on  the  onset  of  T1D,  whereas 
blocking antibody against VCAM-1 delayed the onset of disease (71). 
PECAM-1,  also  called  CD31,  support  homophilic  interactions  and  is 
expressed  by  leukocytes,  platelets  and  endothelial  cells  (63,  64).  In 
vitro,  antibodies  against  PECAM-1  were  demonstrated  to  inhibit 
monocyte  and  neutrophil  migration,  but  not  lymphocyte  migration 
(63). It also could be shown that PECAM-1 knockout mice did not show 
a  diminished  inflammatory  response,  demonstrating  that  PECAM-1  is 
compensable for transmigration in vivo (64, 72). 
Besides endothelial cells CD99 is expressed by erythrocytes and most 
leukocytes.  It  supports  homophilic  interactions  and  also  acts  in 
diabedesis downstream of PECAM-1 (Figure 3) (64, 72). 
Junctional adhesion molecules (JAMs) are expressed at cell junctions in 
epithelial and endothelial cells as well as by leukocytes and platelets. 
Several reports suggest that JAM proteins are important for a variety 
of  cellular  processes,  including  tight  junction  assembly,  platelet 
activation,  angiogenesis,  virus  binding  and  leukocyte  transmigration 
(Figure  3)  (for  more  information  see  chapter:  Junctional  adhesion 
molecules) (73). 
6.6.1.4  Cadherins (VE-cadherin) 
Cadherins are calcium-dependent adhesion molecules that are involved 
in  tissue  organization and  endothelial  cell-contact  stability  (67).  VE-  42
cadherin is highly expressed at adherens junctions and is linked to the 
cell  cytoskeleton  via  catenins.  It  also  plays  its  role  in  leukocyte 
transmigration (72). 
 
Figure 3: Adhesion molecules and their role in the leukocyte adhesion cascade. 
Capturing and rolling is mediated by selectins, activation is caused by chemokines and arrest is 
mediated by the interaction of integrins with ICAM-1 or VCAM-1. Current knowledge suggests 
that leukocytes can transmigrate by two different pathways: the transcellular migration that is 
mediated  by  ICAM-1  and  the  paracellular  migration  in  which  a  lot  of  different  adhesion 
molecules,  such  as  PECAM-1,  CD99  and  JAMs,  are  involved.  (Adapted  from  K.  Ley,  Nature 
Reviews 2007) 
6.7  Junctional adhesion molecules 
6.7.1  Junctional  adhesion  molecule  family  and  its 
origin 
Junctional adhesion molecules are members of the larger CTX protein 
(Cortical  Thymocyte  marker  for  Xenopus)  family,  in  which  ancestral 
precursors may be the origin of T cell and B cell immune receptors. 
Several of these CTX proteins have also been described as receptors 
for various viruses like reovirus and adenovirus (74, 75). JAMs consist 
of a family of three closely related CTX proteins, JAM-A, JAM-B, and 
JAM-C and four members of another CTX subfamily ESAM, CAR, JAM-4, 
and JAML (72).   43
6.7.2  Structure and biochemical properties 
The  classical  JAM  proteins  are  type  1  transmembrane  proteins  that 
have an N-terminal signal peptide, an extracellular domain consisting of 
two extracellular Ig-like domains, a single transmembrane domain and a 
short  cytoplasmic  tail  that  contains  phosphorylation  sites  that  may 
serve as substrates for PKA, PKC and Casein Kinase II. In addition, they 
have a class II PDZ-binding motif at the C-terminal end that appears to 
facilitate interactions with tight junctions-associated scaffold proteins 
such as ZO-1, PAR3, AF-6 and MUPP1 (Figure 4a) (73). 
6.7.3  Tissue expression and cellular localization 
In general, if expressed on endothelial or epithelial cells the classical 
JAM  proteins  are  found  at  tight  junctional  complexes,  where  they 
participate in maintenance and assembly of junctions. 
JAM-A can be found on the surface of endothelial cells and epithelial 
cells  of  various  tissues,  including  the  heart,  liver,  pancreas,  kidney, 
brain, lymph nodes, intestine, lungs, placenta and vascular tissue. The 
expression of JAM-A could also been shown on platelets, monocytes, 
neutrophils, a subset of lymphocytes and on antigen-presenting cells, 
such as macrophages and dendritic cells (62, 64, 74). 
JAM-B is expressed by endothelial cells and is specifically enriched in 
certain  vessels,  such  as  high  endothelial  venules  and  lymphatics. 
Recently  JAM-B  expression  could  be  shown  on  peripheral  mouse 
leukocytes, such as conventional dendritic cells (76). 
JAM-C is highly expressed on high endothelial venules and lymphatics 
and is found on fibroblasts and human epithelial cells. In addition, JAM-
C  is  expressed  by  human  platelets,  monocytes,  neutrophils,  natural 
killer cells, dendritic cells, B cells and a subset of T cells but has not 
yet been detected on mouse leukocytes (62, 77, 78).   44
6.7.4  Properties, interaction and ligands 
JAM  proteins  have  been  implicated  in  a  variety  of  physiology  and 
pathologic  processes  involving  cellular  adhesion.  All  three  JAMs  can 
support homophilic as well as heterophilic interactions. Moreover, JAM-
A  can  interact  with  LFA-1,  whereas  JAM-B  can  support  heterophilic 
interactions  with  JAM-C  and  VLA-4.  Besides  interaction  with  JAM-B, 
JAM-C can also bind the leukocytes integrins Mac-1 and CD11c (Figure 
4b) (62, 79). 
 
Figure  4:  Structure  of  classical  junctional  adhesion  molecules  (JAMs)  and  their 
ligands. 
(A)  All  three  JAMs  have  an  extracellular  domain  with  two  Ig-like  domains,  a  single 
transmembrane sequence, and a short cytoplasmic tail that contains a PDZ binding motif. (B) 
The JAMs can support heterophilic as well as homophilic interactions. JAM-A interact with the 
integrin  lymphocyte  function-associated  antigen  1  (LFA-1),  JAM-B  interacts  with  JAM-C  or 
very late antigen 4 (VLA-4), and JAM-C moreover interacts with Mac-1 and CD11c. (Adapted 
from K. Ebnet, J. of Cell Science 2004 and C. Weber, Nature Reviews 2007) 
6.7.5  The  role  of  JAM-C  in  various  diseases  and 
pancreatitis 
Since  JAM-C  has  been  discovered  and  characterized  ten  years  ago 
many different investigations have proven the importance of JAM-C in 
various  diseases.  JAM-C  is  implicated  in  cell  polarity  formation  in 
myelinated peripheral nerves and spermatid differentiation (80, 81), in 
angiogenesis and tumor growth in mice (82), in vascular permeability   45
(83),  and  leukocyte  adhesion  and  transmigration  (84).  The  role  of 
JAM-C  in  various  diseases  has  been  analyzed  in  vitro a n d  in  vivo i n  
numerous imaging studies and animal models for several diseases. In 
inflammatory pathologies such as peritonitis and arthritis treatment of 
mice with a JAM-C neutralizing antibody reduced the accumulation of 
neutrophils at the side of inflammation (85, 86). In JAM-C knockout 
mice pulmonary dysfunction and reduced IgG memory could be found 
(76, 87). Moreover, the blockade of JAM-B/JAM-C interaction reduced 
the initial monocyte numbers in the lung of mice following intranasal 
LPS  challenge.  However,  this  reduction  of  abluminal  monocytes  was 
not due to a lower transmigration rate of the cells but rather due to 
increased reverse transmigration (88). 
A very interesting study analyzed the role of JAM-C in cerulein-induced 
pancreatitis in mice. JAM-C expression in the pancreas was increased 
after cerulein-treatment of mice. Additional treatment of mice with a 
JAM-C neutralizing antibody led to reduced leukocyte infiltration, acinar 
cell  necrosis  and  oedema.  On  the  other  hand,  if  transgenic  mice 
overexpressing  JAM-C  were  treated  with  cerulein  the  leukocyte 
accumulation at site of injury, tissue damage as well as oedema were 
increased (89). 
These  results  indicate  that  JAM-C  plays  a  pivotal  role  in  various 
inflammatory diseases and its expression in the pancreas contributes 
to  the  development  of  acute  pancreatitis  by  abetting  leukocyte 
extravasation.   46
A I M S   47
7 Aims of the study 
The  goal  of  my  project  was  to  investigate  the  mechanisms 
involved  in  attraction,  activation  and  transmigration  of 
lymphocytes to the target site of injury in type 1 diabetes. 
Aim 1 
Analysis  of  the  impact  of  the  chemokine  receptor  CXCR3 
antagonist NIBR2130 on the development of T1D in the RIP-
LCMV mouse model 
Aim 2 
Characterization  of  the  influence  of  the  adhesion  molecule 
JAM-C on the development of virus-induced T1D 
7.1  Strategy 
As previously described (see chapter: Introduction) T1D results from 
the  autoimmune  destruction  of  insulin-producing  ß  cells  in  the 
pancreas.  Attraction,  activation  and  transmigration  of  inflammatory 
cells, such as T cells, B cells and dendritic cells are prerequisite to ß 
cell-injury.  Such  processes  include  several  molecular  interactions 
between  receptors  expressed  on  circulating  cells  and  chemokines  or 
adhesion molecules expressed on endothelial cells. Thus, our strategy 
was  to  directly  block  the  interaction  of  either  the  key  chemokine 
CXCL10 with its receptor CXCR3 or of the adhesion molecule JAM-C 
with its ligand MAC-1.   48
7.2  Aim 1: Inhibition of CXCR3 during T1D 
Generally,  it  is  believed  that  autoimmune  disease  is  caused  by  the 
combination  of  genetic  predisposition  with  environmental  triggers, 
such as pathogen infection or xenobiotics (see chapter: Introduction). 
In the RIP-LCMV mouse model the target antigens are considered as 
ﾑ‘selfﾒ’ and antigen-specific precursor T cells are ignorant or tolerant to 
these  antigens.  T1D  is  initiated  by  LCMV-infection  that  leads  to  an 
unspecific inflammation in the pancreas resulting in the attraction and 
activation  of  leukocytes  including  LCMV-specific  precursor 
lymphocytes  to  the  site  of  injury.  Along  with  virus  elimination, 
activated  LCMV-specific  T  cells  attack  target  antigens  expressed  by 
transgenic ß cells resulting in a progressive destruction of ß cell-mass 
and subsequently overt diabetes. The initial virus-induced inflammation 
is  triggered  by  the  release  of  chemokines.  Directed  migration  is 
mediated  by  the  interaction  between  chemokines  and  their 
corresponding  receptors  expressed  on  different  leukocytes.  This 
interaction is crucial for the activation and migration of leukocytes to 
the  site  of  injury.  In  this  context  it  was  shown  that  the  chemokine 
CXCL10 that binds to the chemokine receptor CXCR3 plays a pivotal 
role in attracting autoaggressive T cells to the islets of Langerhans in 
T1D.  Neutralization  or  overexpression  of  CXCL10  significantly 
influenced  the  development  of  virus-induced  T1D  in  the  RIP-LCMV 
mouse model (56, 57)(see chapter: Introduction). 
As previously described the main receptor of CXCL10 is CXCR3, a G 
protein-coupled seven-membrane-spanning glycoprotein predominantly 
expressed by activated Th1-type T cells (see chapter: Introduction). It 
was  shown  that  CXCR3-deficient  mice  crossed  with  RIP-LCMV  mice 
showed a significant delay in the development of T1D (60). Moreover,   49
it has also be demonstrated that a preproinsulin specific autoreactive 
CXCR3 expressing CD8+ T cell clone, derived from a type 1 diabetes 
patient, was able to kill human pancreatic ß cells (90). 
Due  to  the  fact  that  CXCL10/CXCR3  interaction  seems  to  play  a 
significant role in autoimmune diseases we investigated the impact of 
the  inhibition  of  CXCR3  with  the  small  molecule  CXCR3  antagonist 
NIBR2130  on  the  outcome  of  virus-induced  T1D  in  the  RIP-LCMV 
mouse model. 
Figure 5: Working hypothesis ﾖ– Project 1 
A: Immunopathogenesis in the RIP-LCMV model: 
(A1) LCMV-infection of the pancreas leads to the release of pro-inflammatory cytokines, such 
as TNF-, by resident antigen presenting cells. (A2) Subsequently, activated endothelial cells 
as well as ß cells release chemokines, such as CXCL10 that is one of the earliest chemokine 
expressed  in  high  local  concentrations  after  LCMV-infection.  (A3)  Through  binding  to  its 
receptor CXCR3, CXCL10 predominantly attracts activated aggressive Th1-type T cells, which 
migrate into the inflamed tissue. (A4) Activated T cells transmigrate through the endothelial 
cell  layer  and  penetrate  the  ß  cells.  (A5)  Infiltrating  LCMV-specific  T  cells  start  destroying 
some transgenic  cells expressing LCMV proteins in a perforin dependent manner. At a later 
stage  professional  antigen  presenting  cells,  such  as  dendritic  cells,  migrate  to  pancreatic 
draining lymph nodes and present LCMV and other islet antigens leading to further proliferation 
and expansion of the autoaggressive T-cell repertoire and subsequently increased infiltration of 
autoaggressive  T  cells  to  the  islets.  (A6)  Finally,  islet  antigen-specific,  aggressive  T  cells 
together with unspecific bystander factors destroy most of the remaining  cell-mass resulting 
in overt diabetes. 
B: Blockade of CXCL10-CXCR3 interaction by NIBR2130 
(B1 and B2) The same events as in figure A1 and A2. (B3) Through binding to the CXCR3 
receptor  the  CXCR3  antagonist,  NIBR2130,  inhibits  the  interaction  between  CXCL10  and 
CXCR3.  (B4)  Subsequently  the  attraction  of  T  cells  is  blocked  resulting  in  a  diminished 
migration of autoaggressive T cells into the islets of Langerhans. NIBR2130 treated RIP-LCMV 
mice should therefore display reduced incidence and severity of T1D.   50
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7.3  AIM 2: JAM-C and its influence on T1D 
Once  arrived  at  the  site  of  inflammation,  namely  the  islets  of 
Langerhans,  the  leukocytes  have  to  extravasate  through  the 
endothelial cell layer to penetrate the islets. Thereby many different 
adhesion  molecules  such  as  selectins,  integrins  and  immunoglobulin-
superfamily  proteins  are  involved  in  leukocyte  rolling,  activation  and 
arrest,  adhesion  strengthening,  crawling  and  finally  paracellular  or 
transcellular  migration  (62).  As  mentioned  previously,  it  has  been 
shown that JAM-C plays a crucial role in several inflammatory diseases 
such as peritonitis, arthritis and cerulein-induced pancreatitis (85, 86, 
89)  (see  chapter:  Introduction).  In  the  cerulein-induced  acute 
pancreatitis  mouse  model  an  increase  of  JAM-C  expression  in  the 
pancreas  could  be  observed.  Further,  blockade  of  JAM-C  with  a 
neutralizing antibody resulted in reduced pancreatitis (89). Although, 
the immunopathogenic processes involved in the destruction of ß cells 
in  the  cerulein  mouse  model  is  different  than  in  human  T1D,  the 
outcome  of  this  study  shows  that  blockade  of  JAM-C  results  in  a 
reduced leukocyte extravasation through the endothelium, which finally 
leads to a diminished local inflammation of islets (89). 
Therefore  in  the  second  part  of  the  project,  I  investigated  whether 
JAM-C  expression  has an  influence  on  virus-induced  T1D  in  the  RIP-
LCMV mouse model. First, T1D development was analyzed in RIP-LCMV 
mice administered with a neutralizing antibody to block JAM-C. Second, 
RIP-LCMV mice have been crossed with mice overexpressing JAM-C on 
endothelial cells.   52
Figure 6: Working hypothesis ﾖ– Project 2 
A: JAM-C neutralization: 
(A1) LCMV-infection of the pancreas leads to the release of pro-inflammatory cytokines, such 
as TNF-, by resident antigen presenting cells. (A2) Subsequently, activated endothelial cells 
as well as ß cells release chemokines, such as CXCL10. Blockade of JAM-C with a neutralizing 
antibody prevents the interaction between Mac-1, expressed on attracted aggressive T cells 
and  JAM-C  expressed  on  endothelial  cells  surrounding  islets.  (A3  and  A4)  Subsequently, 
transmigration of aggressive T cells is reduced and complete destruction of the ß cell-mass is 
prevented. 
B: JAM-C overexpression: 
(B)  The  same  events  as  in  figure  1A  except  that  due  to  the  overexpression  of  JAM-C  on 
endothelial cells the transmigration  of activated T cells through the endothelial cell layer  of 
islets is increased. This might lead to increased ß cell-destruction and accelerated T1D.   53
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8 Results 
8.1  Project 1: CXCR3 and its role in T1D 
In  the  first  part  of  my  project  I  investigated  the  influence  of  the 
inhibition  of  CXCR3  with  the  CXCR3  antagonist  NIBR2130  on  the 
outcome of T1D. 
8.1.1  Implantation of osmotic pumps guarantees a 
constant delivery of sufficient NIBR2130 
To ensure a constant blockade of CXCR3 a model 2002 osmotic pump 
from Alzet (Cupertino, CA) releasing 0.5 µl/h NIBR2130 or buffer alone 
was implanted under the skin of mice for 4 weeks. The concentration 
in  the  pumps  used  was  16.7  mg/ml,  which  corresponds  to  200  µg 
NIBR2130 per day. Due to its maximal capacity of 250 µl the pumps 
had  to  be  exchanged  after  two  weeks.  This  approach  provided  a 
continuous and constant delivery of the antagonist as demonstrated 
by the blood concentration of NIBR2130 (Figure 7A and Figure 8A). 
Blood levels reached concentrations of 250 to 500 ng/ml. It has been 
demonstrated  before  that  the  half  maximal  inhibitory  concentration 
(IC50)  for  NIBR2130  is  85.2  ng/ml  (91).  In  our  study  we  found  a 
continuous NIBR2130 blood concentration, which was approximately 3 
to 6 times higher than the IC50 of this compound. Thus, implantation of 
osmotic pumps reliably delivers NIBR2130 at a concentration that is 
sufficient for CXCR3 blockade.   56
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Figure 7: Inhibition of CXCR3 in RIP-LCMV-GP mice has no influence on T1D. 
(A) Osmotic pumps were filled with NIBR2130 or buffer implanted under the skin of RIP-LCMV-
GP mice and exchanged after two weeks. The delivery of the antagonist was verified by the 
measurement of the blood concentration of NIBR2130 at different times as indicated. Dotted 
line displays the IC50 of NIBR2130 (B and C) Antagonist-treated and untreated RIP-LCMV-GP 
mice were infected with a single dose of 5 x 104 pfu LCMV on day zero, and blood glucose was 
measured at days indicated (values >300 mg/dl were considered diabetic). Data are the mean 
± SEM of 10-11 mice per group. 
8.1.2  Inhibition  of  CXCR3  significantly  delays  the 
outcome of disease in RIP-LCMV-NP mice 
Next  I  investigated  how  blockade  of  the  CXCR3-CXCL10  interaction 
influences the development of autoimmune diabetes. Osmotic pumps 
filled with NIBR2130 or buffer were implanted into RIP-LCMV-GP and 
RIP-LCMV-NP mice for 4 weeks. One day after pump implantation the 
mice  were  infected  with  5  x  104  pfu  LCMV  and  blood  glucose  was 
measured on days indicated. No significant reduction in blood glucose   57
levels and diabetes incidence or onset were detected in RIP-LCMV-GP 
mice (fast-onset diabetes) treated with NIBR2130 compared to control 
mice (Figure 7B and C). 
 
Figure  8:  Inhibition  of  CXCR3  in  RIP-LCMV-NP  mice  significantly  delays  the 
outcome of T1D. 
(A) Osmotic pumps were filled with NIBR2130 or buffer and were implanted under the skin of 
RIP-LCMV-NP mice and exchanged after two weeks. The delivery of the antagonist was verified 
by the measurement of the blood concentration of NIBR2130 at different times as indicated. 
Dotted line displays the IC50 of NIBR2130 (B-D) Antagonist-treated and untreated RIP-LCMV-NP 
mice were infected with a single dose of 5 x 104 pfu LCMV on day zero, and blood glucose was 
measured at days indicated (values >300 mg/dl were considered diabetic). Note, in (B) the 
same  data  as in (C) are shown except that  the incidence is  only shown until day 28  post 
LCMV-infection to give an improved view of the significant delay in the development of T1D. 
Data are the mean ± SEM of 14-18 mice per group. 
In  contrast,  onset  of  diabetes  was  significantly  delayed  in  the 
antagonist-treated  RIP-LCMV-NP  (slow-onset  of  diabetes)  mice 
compared  to  control  animals  (Figure  8C  and  D).  Interestingly,  the 
majority  of  NIBR2130-treated  mice  turned  diabetic  around  day  35   58
after LCMV-infection (Figure 8C), which is immediately after the pumps 
have been removed and the antagonist concentration has dropped to 
baseline  level  (Figure  8A).  Thus,  it  seems  that  only  a  continuous 
delivery of the CXCR3 antagonist NIBR2130 inhibits the development 
of virus-induced T1D. 
These experiments indicate that a continuous blockade of CXCR3 might 
have an influence on virus-induced diabetes by delaying the incidence 
of disease in the slow-onset but not in the more aggressive fast-onset 
diabetes model. 
8.1.3  Inhibition  of  CXCR3  has  no  effect  on  ß  cell 
function 
To  investigate  the  impact  of  the  neutralization  of  CXCR3  on  ß  cell 
function within islets NIBR2130-treated and control mice infected with 
LCMV  were  analyzed  by  glucose  tolerance  experiments.  At  day  28 
after LCMV-infection mice that have not turned diabetic by that time 
were challenged with a single i.p. injection of 1.5 mg/g body weight 
glucose  and  the  efficiency  of  regulating  the  blood  glucose  to 
normoglycemia  was  assessed  over  time.  Both  the  NIBR2130  treated 
and the control mice showed increased blood glucose values of ~ 300 
mg/dl at 10 minutes after glucose injection. The blood glucose levels 
declined  similarly  in  NIBR2130-treated  and  control  mice,  with  an 
approximate half-life of 20 minutes (Figure 9A). When the same assay 
was performed at day 49 post LCMV-infection NIBR2130-treated mice 
showed  a  slight  but  not  significantly  accelerated  down-regulation  of 
blood glucose compared to untreated control mice (Figure 9B).   59
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Figure 9: Inhibition of CXCR3 has no positive effect on impaired ß cell function. 
Glucose tolerance assay. (A and B) At day 28 (A) and 49 (B) after 5 x 104 pfu LCMV-infection 
groups  of  3-4  NIBR2130-treated  and  untreated  RIP-LCMV-NP  mice  were  challenged  with  a 
single  i.p.  injection  of  1.5  mg/g  body  weight  glucose,  and  blood  glucose  was  measured  at 
different  time  points  as  indicated.  Data  are  the  mean  ±  SEM  of  3-4  non-diabetic  mice  per 
group. 
8.1.4  Inhibition of CXCR3 has no influence on islet 
infiltration in virus-induced T1D 
In order to identify the immunological mechanisms responsible for the 
significant delay in the onset of T1D, cellular infiltration of different 
leukocytes  into  the  islets  of  Langerhans  was  analyzed  by 
immunohistochemistry  and  an  infiltration  score  was  applied  for 
statistical  analysis.  One  possibility  might  be  a  decreased  infiltration 
rate  of  aggressive  islet-antigen-specific  T  cells.  An  alternative 
explanation  for  the  delayed  disease  onset  might  be  an  increased 
recruitment of Tregs. Therefore, we compared protected, non-diabetic 
RIP-LCMV-NP mice treated with NIBR2130 with diabetic control mice 
(three mice per group) at day 28 after 5 x 104 pfu LCMV-infection. 
Pancreas sections were stained for insulin production as well as cellular 
infiltration by CD8+ T cells, T regs, NK cells and CXCR3 expressing cells 
(Figure 10A). All mice assessed showed a similar reduction of insulin 
production  as  well  as  a  similar  infiltration  pattern  of  the  different 
immune cells analyzed. No difference between NIBR2130-treated and   60
untreated  animals  was  observed.  Interestingly,  in  NIBR2130-treated 
mice the amount of cells expressing CXCR3 within the infiltrations of 
islets  was  the  same  as  in  control  mice  (Figure  10A).  Moreover, 
independently of the disease pattern islets from both mouse groups 
showed  similar  infiltration  rates  (Figure  10B).  Some  morphologically 
viable  islet  cells  with  insulin  expression  were  found  in  both  mouse 
groups.  Nevertheless,  most  islets  were  already  infiltrated  and  more 
than  30%  of  all  islets  analyzed  had  heavy  intra-insular  infiltration 
and/or remained as ﾑ‘islet-scarsﾒ’. Moreover, cells infiltrating islets were 
predominantly of the CD8+ phenotypes and the amount of Tregs within 
islets was not increased in the NIBR2130-treated mice compared with 
control animals. Approximately 10 Tregs per mm2 area of infiltration were 
found  in  both  mouse  groups  analyzed  (Figure  10C).  These 
observations indicate that the observed delay in the onset of T1D is 
not due to a decreased infiltration rate or a redistribution of specific T 
cell subsets such as Tregs. 
8.1.5  Neutralization  of  CXCR3  has  no  significant 
influence on the functional activity of LCMV-
specific lymphocytes 
CD8+ T cells specific for the NP396 peptide and the assistance of CD4+ T 
cells are required to cause diabetes in RIP-LCMV-NP mice. Therefore, 
the  functional  activity  of  antigen-specific  T  cells  after  CXCR3 
neutralization  was  assessed  by  staining  for  intracellular  cytokines 
(ICCS) produced by T cells after ex vivo stimulation.   61
 
Figure  10:  Inhibition  of  CXCR3  has  no  impact  on  different  cell  types  infiltrating 
islets. 
(A) Pancreas sections of NIBR2130-treated and untreated RIP-LCMV-NP mice at day 28 after 
LCMV-infection were probed for insulin production and infiltrations by CD8+ T cells, Tregs, NK 
cells and CXCR3 expressing cells. (B) Insulitis score was obtained from sections of 3 mice per 
group  (n=36,  islets  analyzed).  Scoring  system:  0,  no  infiltration;  1,  some  peri-insular 
infiltration; 2, heavy peri-insular infiltration with some intra-insular infiltrates; 3, heavy intra-
insular infiltration and/or islet scars. (C) Evaluation of the amount of Tregs per mm2 area of islet 
infiltration. Data are the mean ± SEM of 3 mice per group.   62
The different T cell subsets were overnight ex vivo stimulated with the 
immunodominant LCMV-NP396 or LCMV-GP33 peptide presented on MHC 
class I H-2Db and with the LCMV-GP61 peptide presented on MHC class II 
H-2IAb  molecules.  Therefore,  mice  were  treated  with  NIBR2130  by 
subcutaneously implanted osmotic pumps one day before 5 x 104 pfu 
of LCMV-infection in RIP-LCMV-NP mice. At day 7 and day 28 post-
infection splenocytes as well as lymphocytes from pancreatic draining 
lymph nodes (PDLN) were isolated and different T cell subsets were 
analyzed for intracellular IFN- production after over night stimulation 
with NP396, GP33 or GP61 peptides. On day 7 post-infection in the spleen 
of untreated control mice, approximately 7% and 2-3% of CD8+ T cells 
were GP33- and NP396-specific, respectively. Moreover, a slight reduction 
was  observed  for  both  GP33-  and  NP396-specific  CD8+  T  cells  in  the 
spleen as well as in the PDLN of NIBR2130-treated mice compared to 
control animals (Figure 11B). In contrast, only a few GP61-specific CD4+ 
T cells were found in both mouse groups (Figure 11C). On day 28 after 
LCMV-infection, no difference between NIBR2130-treated and control 
mice was found for the NP396-specific CD8+ T cells in the spleen as well 
as in the PDLN, whereas an increase of GP33-specific CD8+ T cells in the 
spleen was detected in antagonist-treated mice compared with control 
animals (Figure 11D). In spite of minimal differences in the presence of 
IFN- producing LCMV-specific T cells in NIBR2130-treated compared 
to control mice these data indicate that the neutralization of CXCR3 
has no significant effect on the functional activity of LCMV-specific T 
cells in the spleen as well as in the PDLN during both the acute, anti-
viral phase (day 7) as well as the memory, autoimmune phase (day 28) 
(Figure 11).   63
 
Figure  11:  Inhibition  of  CXCR3  has  no  significant  influence  on  the  functional 
activity of LCMV-specific T cells. 
(A)  Representative  dot  plots  of  splenocytes  of  an  NIBR2130-treated  (upper  panel)  and 
untreated  (lower  panel)  control  mouse  7  days  post-infection  stained  for  surface  CD8  and 
intracellular IFN- (left side, GP33 stimulated; middle, NP396 stimulated; right side, unstimulated) 
(B-D) The presence of GP33-,  NP396- and GP61-specific T cells on day 7 and 28 after LCMV-
infection in the spleen and PDLN of NIBR2130-treated and untreated RIP-LCMV-NP mice was 
analyzed by ICCS (IFN-) after o/n in vitro stimulation with GP33, NP396 or GP 61 peptide. Data 
are the mean of 4-6 mice per group. (B and D) GP33-, NP396- specific  CD8+ T cells. (C) GP61-
specific CD4+ T cells.   64
8.2  Project 2: JAM-C and its role in T1D 
In  this  part  of  the  project  the  influence  of  JAM-C  on  rolling  and 
transmigration of leukocytes in T1D was characterized. 
8.2.1  LCMV-infection  results  in  an  upregulation  of 
JAM-C around the islets of Langerhans  
To assess the kinetics of JAM-C expression pancreata from RIP-LCMV-
GP  mice  were  harvested  at  day  0,  4,  7,  10,  14,  and  28  after  i.p. 
infection  with  1  x  104  pfu  LCMV  and  analyzed  by 
immunohistochemistry  or  immunofluorescence  staining.  JAM-C  was 
upregulated around the islets predominantly at days 10 and 14 after 
LCMV-infection  (Figure  12  left  panel  and  Figure  13A).  Interestingly, 
islet infiltration was most pronounced at the time of strongest JAM-C 
expression (Figure 12 and Figure 13A right panel). At day 10 to 14 
post-infection most islets of LCMV-infected RIP-LCMV-GP mice showed 
massive peri- and intra-islet CD8+ T cell infiltrations (Figure 12 right 
panel and Figure 13A right panel). The presence of high numbers of T 
cells in and around the islets resulted in the destruction of islet cells 
and impaired ß cell function that finally led to overt disease (Figure 12 
middle panel). 
For  immunofluorescence  stainings  the  constitutively  expressed 
adhesion molecule, CD31, was used as an endothelial cell marker and 
the colocalization of JAM-C and CD31 was characterized by confocal 
microscopy  (Figure  13B).  Endothelial  cells  from  pancreatic  blood 
vessels are double-stained with JAM-C and CD31 (Figure 13A and B). 
As seen previously (Figure 12) a significant increase in fluorescence 
intensity  of  JAM-C  expression  was  detected  at  day  10  to  14  after 
LCMV-infection (Figure 13C).    65
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Figure  12:  JAM-C  expression  correlates  with  islet  infiltration  and  functional 
impairment. 
Pancreas sections of RIP-LCMV-GP mice were probed for JAM-C expression, insulin production 
and CD8+ T cell infiltrations at different times after LCMV-infection.   66
For this analysis a histogram showing the average light intensity of the 
individual  fluorescence  channels  in  the  image  was  performed.  In 
comparison  to  day  0,  days  2,  7,  21  and  28  showed  significant 
differences with a p-value p < 0.05, whereas day 14 (p = 0.0015) and 
day  10  (p  =  0.0001)  showed  a  highly  significant  increase  in  the 
fluorescence  intensity  (Figure  13C).  Additionally,  these  stainings 
confirmed the observation made in Figure 12 concerning the overlap 
between the increase of JAM-C expression and the peak of CD8+ T cell 
infiltration (Figure 13A). 
These experiments indicate that JAM-C is upregulated in the pancreas 
upon  LCMV-infection  and  might  therefore  play  a  role  in  the 
immunopathogenesis of T1D in the RIP-LCMV model. 
8.2.2  JAM-C  blockade:  Neutralization  of  JAM-C 
results in a decreased T1D incidence 
Because JAM-C expression was upregulated around the islets at day 10 
to  14  post  LCMV-infection,  at  the  peak  of  islet  infiltration,  the 
influence  of  JAM-C  expression  on  the  pathogenic  processes  of  T1D 
particularly islet infiltration of autoaggressive T cells resulting in ß cell-
destruction, was assessed. JAM-C was blocked with a neutralizing anti-
JAM-C  antibody  that  disrupts  murine  JAM-B/-C  interactions  (79).  In 
RIP-LCMV-GP  mice  anti-JAM-C  antibody  (100  µg  each  injection)  was 
administered i.p. one day before 1 x 104 pfu LCMV-infection and then 
at days 1, 2, 5,  8, 11, and 14 post-infection. Anti-JAM-C antibody-
treated as well as control RIP-LCMV-GP mice displayed a similar initial 
diabetes  incidence  of  more  than  60%  within  the first  21  days after 
LCMV-infection.   67
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Figure 13: Expression of JAM-C after LCMV-infection. 
(A)  Pancreas  sections  of  RIP-LCMV-GP  mice  at  different  times  after  LCMV-infection  were 
analyzed for CD31 (red, left) and JAM-C (green) expression and CD8+ T cell infiltrations (red, 
right)  in  the  islets  of  Langerhans.  (B)  Colocalization  analyzed  for  JAM-C  (green)  and  CD31 
(red)  expression.  (C)  Evaluation  of  fluorescence  intensity  of  JAM-C  expression  at  different 
times  after  LCMV-infection.  Bars  representing  mean  of  3-8  islets  each  time  point  and 
statistical significance of the fluorescence intensity relative to day 0 were determined using 
the unpaired t test (*, p < 0.05; **, p < 0.005; ***, p < 0.0005).   68
Interestingly, neutralization of JAM-C lead to a reversion of T1D two 
months  after  LCMV-infection  in  that  only  30%  of  the  anti-JAM-C 
antibody-treated mice remained diabetic compared to 60% of diabetic 
control animals. Reverting mice remained non-diabetic throughout the 
whole observation period (Figure 14A). In RIP-LCMV-NP mice anti-JAM-
C  antibody  (100  µg  each  injection)  was  administered  i.p.  one  day 
before 1 x 104 pfu LCMV-infection and then at days 1, 3, 7, 11, 14, 
18, 22, 26, 29, and 34 post-infection. 
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Figure 14: Neutralization of JAM-C reduces the development of T1D. 
RIP-LCMV-GP (A) and RIP-LCMV-NP (B) mice were infected with LCMV. Mice were treated with 
100 µg of anti-JAM-C mAb (H33) (closed circles) or were left untreated (open circles). Blood 
glucose was measured at weekly intervals (values >300 mg/dl were considered diabetic). Data 
are the mean ± SEM of 8-10 mice per group. 
In the RIP-LCMV-NP mice the incidence of diabetes in JAM-C antibody-
treated mice was slightly delayed and reduced to 30% compared to an 
incidence  of  50%  in  control  mice  (Figure  14B).  The  rather  high 
variation (SEM) in blood glucose values seen in the RIP-LCMV-GP as well   69
as  in  the  RIP-LCMV-NP  mice  is  due  to  the  fact  that  some  mice  are 
already  diabetic  with  blood  glucose  levels  of  up  to  600  mg/dl  and 
other are still in a non-diabetic region of <200 mg/dl. In addition, islet 
infiltration  in  RIP-LCMV-NP  mice  treated  with  JAM-C  neutralizing 
antibody and control-treated animals was compared at the end point 
(six  months  after  LCMV-infection).  For  semi-quantitative  assessment 
of the islet infiltration, an infiltration score was applied and statistical 
evaluation was performed after double blind analysis of the data. No 
significant difference in islet infiltration was found in antibody-treated 
mice compared to control animals (Figure 15). 
Nevertheless, the blocking studies in RIP-LCMV mice indicate that JAM-
C plays a role in the pathogenesis of T1D, since neutralization of JAM-C 
resulted  in  a  reversion  of  T1D  in  the  fast-onset  RIP-LCMV-GP  model 
and a reduction of disease in the slow-onset RIP-LCMV-NP mouse line. 
 
Figure 15: Neutralization of JAM-C has no influence on insulitis six months after 
LCMV-infection in RIP-LCMV-NP mice. 
Insulitis score was determined in pancreas sections of 8-9 RIP-LCMV-NP mice per group that 
have been stained for CD8+ T cells (brown) (n=140, islets analyzed). Scoring system: 0, no 
infiltration; 1, some peri-insular infiltration; 2, heavy peri-insular infiltration with some intra-
insular infiltrates; 3, heavy intra-insular infiltration and/or islet scars.   70
8.2.3  JAM-C  blockade:  The  frequency  of  LCMV-
specific  T  cells  is  not  reduced  after 
neutralization of JAM-C 
Due to the fact that the blockade of JAM-C resulted in a reduction of 
the development of T1D the influence of JAM-C neutralization on the 
functional  activity  of  LCMV-specific  T  cells  was  analyzed.  Therefore, 
anti-JAM-C antibody (100 µg each injection) was administered i.p. one 
day before 1 x 104 pfu LCMV-infection and then at days 1, 3, 7, 11, 
14,  18,  22  and  26  post-infection.  At  day  7  and  28  post-infection 
lymphocytes from the spleen and the PDLN were isolated and stained 
for  CD8,  CD4  and  IFN- a f t e r  o v e r n i g h t  s t i m u l a t i o n  w i t h  t h e  
immunodominant LCMV-peptides NP396, GP33, and GP61. At day 7 post-
infection a slight reduction of GP33-specific CD8+ T cells, which in RIP-
LCMV-NP  mice  reflect  the  anti-viral  response  rather  than  the 
autoimmune reaction, was observed in the spleen and PDLN of anti-
JAM-C antibody-treated mice compared to control animals. In contrast, 
a slight increase in GP33-specific CD8+ T cells was found in the anti-JAM-
C  antibody-treated  mice  compared  to  control  animals  during  the 
autoimmune phase on day 28 after LCMV-infection. The autoimmune 
response  represented  by  NP396-specific  CD8+ T  c e l l s  s h o w e d  s i m i l a r  
appearance  of  IFN- p r o d u c i n g  C D 8 + T  c e l l s  u p o n  N P 396  ex  vivo 
stimulation in the spleen as well as PDLN from both mouse groups at 
day 7 as well as day 28 (Figure 16A). As negative control a wildtype 
C57BL/6  mouse  was  included  into  all  experiments.  As  previously 
mentioned  in  the  RIP-LCMV-NP  mice  the  LCMV-NP  transgene  is 
expressed  in  the  ß  cells  as  well  as  in  the  thymus  resulting  in  the 
deletion of high-affinity NP-specific T cells. This leads to low-affinity 
NP-specific CD8+ T cells in the periphery being not sufficient to induce   71
diabetes  after  LCMV-infection.  For  this  reason  they  need  the 
assistance  of  CD4+  T  cells  to  induce  T1D  and  due  to  that  fact  the 
functional activity of GP61-specific CD4+ T cells was assessed. At both 
time points approximately 1% of CD4+ T cells were found to be GP61-
specific in all groups. In particular, no difference between anti-JAM-C 
antibody-treated and control animals was found at either day 7 or day 
28  after  LCMV-infection  (Figure  16B).  Finally,  those  results  indicate 
that  the  neutralization  of  JAM-C  resulting  in  a  reduction  in  the 
outcome of virus-induced diabetes is not due to a decreased presence 
of LCMV-specific T cells.   72
 
Figure 16: Neutralization of JAM-C has no significant influence on the functional 
activity of LCMV-specific T cells. 
The presence of GP33-, NP396- and GP61-specific CD8+ (A) and CD4+ (B) T cells on day 7 and 28 
after LCMV-infection in the spleen and PDLN of anti-JAM-C antibody-treated and untreated RIP-
LCMV-NP mice was analyzed by ICCS (IFN-) after o/n in vitro stimulation with GP33, NP396 or 
GP61 peptide. Data are the mean of 3-4 mice per group. (A) GP33-, NP396- specific CD8+ T cells. 
(B) GP61-specific CD4+ T cells. As internal controls unstimulated cells as well as lymphocytes 
from a wildtype C57BL/6 mouse (wt) were used.   73
8.2.4  JAM-C blockade: In vivo assessment of CD8+ 
T  cell  extravasation  and  ß  cell-killing  in  a 
peptide/adjuvant transfer model 
Due  to  the  fact  that  after  LCMV-infection  expression  of  JAM-C  is 
increased at the peak of islet infiltration and that blocking of JAM-C 
leads  to  a  reduction  of  T1D  we  tried  to  visualize  by  two-photon 
microscopy  the  involvement  of  JAM-C  in  the  real-time  kinetics  of 
cellular migration of diabetogenic T cells around the islets. The model 
used for our investigations employs the RIP-LCMV-GP x MIP-GFP mice 
that  are  expressing  the  green  fluorescent  protein  (GFP)  under  the 
control of the mouse insulin promoter (MIP) specifically in the ß cells of 
Langerhans.  To  visualize  the  autoreactive  T  cells  1.5  x  107 n a ï v e  
splenocytes of DsRed+ TCR-transgenic P14 mice, which harbor CD8+ T 
cells specific for the GP33 epitope, were transferred intravenously into 
RIP-LCMV-GP x MIP-GFP mice on day 0. One and 3 days later the mice 
were immunized i.p. with 2 mg GP33 peptide and additionally with 50 µg 
of  Toll-like  receptor  (TLR)  9-binding  CpG  to  initiate  proinflammatory 
reactions. Six days after adoptive transfer of P14 splenocytes, 500 µg 
of TLR3-binding virus-related double stranded RNA-repeat polyinosinic-
polycytidylic  acid  (Poly(I:C))  was  administered  i.p.  to  mimic  a  viral 
infection and to upregulate the MHC class I molecules. In this in vivo 
peptide/adjuvant  stimulation  model  the  DsRed+ G P 33-specific  CD8+ T  
cells  got  activated  and  migrated  to  the  pancreas  where  GP  is 
expressed on pancreatic ß cells. This led to the destruction of ß cells 
followed  by  the  development  of  diabetes  in  a  highly  synchronized 
fashion  within  8  to  10  days  after  P14  transfer  (Figure  18A).  This 
migration into pancreas and the interaction between splenocytes and ß 
cells  was  further  visualized  by  the  two-photon  microscopy,  which   74
enabled  the  detection  of  red  fluorescent  splenocytes  within  green 
islets. To achieve this in vivo visualization of islet cells on cellular basis 
in  real-time,  a  complex  surgical  preparation  of  the  pancreas  was 
performed.  The  mouse  was  first  anesthetized  with  a  ketamine  (120 
mg/kg) / xylazine (6 mg/kg) mixture (injected i.p.). After shaving the 
belly area the skin was cleaned with 70% isopropanol and an incision 
was  made  into  the  abdominal  region  to  expose  the  spleen  and  the 
pancreatic tail region (Figure 17A). After removing of the spleen by 
cauterizing the splenic arteries, the pancreatic tail was gently exposed, 
fixed with glue on a custom-designed imaging stage and immersed in 
saline buffer (Figure 17B and C). To ensure an  in  vivo situation the 
vascular  supply  and  oxygen  pressure  had  to  be  kept  intact  and  the 
body  temperature  had  to  be  maintained  during  the  whole  imaging 
process.  Therefore,  the  custom-designed  imaging  stage  was 
surrounded with a basin filled with saline buffer that was continuously 
heated to 37°C by heating staves (Figure 17D). Finally, the mouse on 
the  custom-designed  imaging  stage  was  carried  to  the  two-photon 
microscopy for visualization of the infiltrated islets (Figure 17E and F). 
On a routine basis the mouse remained for 2-4 hours on the imaging 
stage for intra-vital microscopy and recording of cellular migration into 
the islets of Langerhans. 
In our study two mice challenged with the peptide/adjuvant transfer 
model were repeatedly treated with anti-JAM-C antibody (100 µg) at 
days -1, 1, 3, 5 and 6. We found that the blockade of JAM-C did not 
alter  the  kinetics  of  diabetes  onset,  with  both  animals  that  were 
analyzed  by  two-photon  microscopy  turning  hyperglycemic  in  the 
expected  time-range  between  day  7  and  9  compared  with 
peptide/adjuvant  challenged  but  antibody  untreated  control  mice 
(Figure 18B).   75
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Figure  17:  Surgical  preparation  of  the  pancreas  for  real-time  imaging  by  two-
photon microscopy. 
(A) Before surgery, the mouse was anesthetized and belly area was cleaned and shaved. An 
incision was made in the belly region and after exposing the spleen and the pancreatic tail 
region the spleen was cauterized from the pancreas. (B and C) The pancreatic tail was fixed 
with glue on a custom-designed imaging stage and immersed in saline buffer. (D) The imaging 
stage was surrounded with a saline buffer filled basin that was continuously heated to 37°C. (E 
and F) The entire real-time imaging stage including the two-photon microscope. 
Nevertheless, the extravasation and islet infiltration of aggressive P14-
splenocytes might be affected by the anti-JAM-C antibody treatment. 
Therefore, the diabetogenic immune response at two distinct phases,   76
i.e. around the diabetic threshold in an animal that turned diabetic at 
day 8 post transfer with a blood glucose value marginally over 300 
mg/dl and in a already severely diabetic one at day 7 post transfer, 
with  blood  glucose  over  500  mg/dl,  was  analyzed.  The  relative 
contribution of CD4+ T cells, CD8+ T cells and B cells was determined 
by flow cytometry and it was found that the majority of infiltrated cells 
in the pancreas were CD8+ T cells (Figure 18C). B cells and CD4+ T cells 
represented  only  a  minor  component  in  mouse  2,  whereas  both 
subsets were virtually absent in mouse 1. Due to the GP33-specific in 
vivo s t i m u l a t i o n ,  C D 8 + T  c e l l s  w e r e  g e n e r a l l y o v e r r e p r e s e n t e d  i n  t h e  
spleen. 
ß cell decay was evident in vivo in both mice, and is best shown by 
presence of single ß cell clusters as observed in mouse 2 (Figure 18D, 
white arrows). In addition, real-time 3D monitoring of vascular stainings 
revealed extensive vasodilatation of the microvasculature surrounding 
the  islets  (Figure  18D).  The  fact  that  the  blood  flow  was  fully 
maintained  also  confirmed  the  physiologic  conditions  of  our  imaging 
approach. In mouse 1, an extensive DsRed+ infiltrate was visualized in 
the immediate neighborhood of the ß cells (Figure 18D). In line with 
previous  findings  during  the  early  diabetic  phase  of  this  model,  the 
majority of the cells appeared to arrest in attachment to the ß cells for 
prolonged time periods. Such arrest was verified in 3 individual islets 
for approximately 5 minutes. 
Finally,  a  60  minutes  3D  image  series  of  the  in  vivo b e h a v i o r  o f  
diabetogenic  cells  during  the  late  stage  of  diabetes  development  in 
mouse  2  (Figure  19B)  was  compared  with  a  peptide/adjuvant 
challenged  RIP-LCMV-GP  x  MIP-GFP  control  mouse  (Figure  19A). 
Continuous local circulation along the entire duration of the movie was   77
verified by the sporadic detection of rapidly moving DsRed+ cells in the 
blood flow (Figure 19B ﾖ– first frame, red lines). 
 
Figure 18: Jam-C blockade does not prevent CD8+ T cell extravasation and ß cell 
killing in vivo in the transfer model with peptide/adjuvant challenge. 
(A) Schematic presentation of the peptide/adjuvant challenged model. 1.5 x 107 DsRed+ P14 
splenocytes  were  transferred  to  RIP-LCMV-GP  x  MIP-GFP  mice  at  day  0  and  subsequently 
stimulated in vivo with 2 mg GP33 peptide and 50 µg CpG i.p. at day 1 and 3. Finally, 500 µg 
Poly(I:C) was injected i.p. at day 6. (B) Diabetes incidence in two groups of RIP-LCMV-GP mice 
challenged  with  peptide/adjuvant.  Additionally  one  group  was  treated  with  100  µg  of  anti-
JAM-C mAb at days -1, 1, 3, 5 and 6 (as arrows indicated). (C) CD8+ T cell, CD4+ T cell and B 
cell populations in spleen and pancreas of anti-JAM-C mAb treated group. (D) Visualization of 
pancreatic islet cells by two photon-microscopy of an untreated healthy control and of two 
anti-JAM-C  mAb  treated  and  peptide/adjuvants  challenged  mice  (red  dots,  DsRed+ P 1 4  
splenocytes; green, ß cells expressing GFP; red network, vascular system). 
The final time frames of the Figure 19B show the real-time injection of 
fluorescently labeled dextran in order to provide accurate orientation 
of the vascular network. The islets had likely lost some of their ß cell 
mass  as  seen  in  their  irregular  shape  but  obviously  still  provided  a 
significant source of MHC-presented antigen enabling a minority of the 
cells to arrest (Figure 19A and B, e.g. yellow arrowheads in the first   78
frame).  There  were  different  migration  behaviors  of  individual  cells 
observed  during  the  whole  imaging  procedure.  To  visualize  this 
migration pattern the DsRed+ cells had have been marked by red lines. 
Some DsRed+ cells just passed by, whereas some seemed to interact 
with remaining intact ß cells. One cell stuck out by moving to a ß cell, 
arresting  there  for  several  minutes,  moving  away  and  moving  back 
once more before leaving the islet (Figure 19B). 
Compared  to  the  diabetogenic  behavior  of  a  peptide/adjuvant 
challenged  RIP-LCMV-GP  x  MIP-GFP  control  mouse  blocking  of  JAM-C 
did  not  prevent  diabetogenic  T  cells  extravasation,  destruction  of  ß 
cells followed by the development of T1D in the P14-transfer RIP-LCMV 
model.   79
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Figure  19:  60  minutes  3D  image  series  of  the  in  vivo  behavior  of  diabetogenic 
cells during diabetes development. 
Intravital/two-photon microscopy at day 8 after peptide/adjuvants challenge. 60 minutes 3D 
image series of the migration of DsRed+ P14 splenocytes (red) to the islets of Langerhans of 
RIP-LCMV-GP  x  MIP-GFP  mice  (green)  without  (A)  or  with  treatment  of  JAM-C  neutralizing 
antibody (B). (A and B) Yellow arrowheads indicate ß cells with a significant source of MHC-
presented antigen enabling a minority of the cells to arrest. (B) Red lines at time 0 mimic a 
pancreatic vessel. White arrowheads show phagocytic cells carrying ß cell-derived GFP locally 
engaging  in  interactions  with  T  cells.  Red  marks  visualize  the  migration  behavior  of  some 
DsRed+ splenocytes. After 60 minutes a fluorescently labeled dextran was injected to visualize 
the vascular network.   81
8.2.5  JAM-C  overexpression:  Characterization  of 
JAM-C  expression  on  pancreatic  endothelial 
cells of transgenic pHHNS-JAM-C mice 
Pancreatic  JAM-C  expression  was  characterized  in  transgenic  mice 
overexpressing JAM-C under control of the Tie2-promotor specifically 
on endothelial cells (pHHNS-JAM-C mice) (92).  Pancreas sections from 
pHHNS-JAM-C  transgenic  and  wildtype  mice  were  analyzed  by 
immunofluorescence  staining.  In  particular,  pancreas  tissue  sections 
were  double-stained  with  JAM-C  and  CD31,  which  was  used  as  a 
specific endothelial cell marker. We found colocalization of JAM-C and 
CD31 on pancreatic blood vessels throughout the whole section and an 
increase  in  JAM-C  expression  in  the  pancreas  of  pHHNS-JAM-C 
transgenic mice compared with wildtype animals (Figure 20A). Western 
blotting  using  total  tissue  lysates  of  pHHNS-JAM-C  transgenic  mice 
compared  to  control  mice  revealed  an  increase  in  JAM-C  expression 
predominantly  in  the  lung  and  the  liver.  However,  no  JAM-C 
upregulation  was  detected  in  total  tissue  lysate  of  pancreata  of 
uninfected  pHHNS-JAM-C  transgenic  mice  compared  with  control 
animals  (Figure  20B).  One  observation  for  this  discrepancy  between 
the results obtained from immunohistochemistry and Western blotting 
might  be  that  the  observed  increase  of  JAM-C  expression  in  the 
immunofluorecence  evaluations  was  restricted  locally  to  pancreatic 
blood  vessels.  Therefore,  the  use  of  total  tissue  lysate  might  have 
resulted in a dilution of the JAM-C signal to a degree that did not allow 
for detection of the JAM-C upregulation by Western blot analysis. Even 
at day 10 after LCMV-infection no upregulation of JAM-C expression 
was  found  although  our  initial  studies  demonstrated  that  JAM-C 
expression is increased at day 10 to 14 after LCMV-infection (Figure   82
13  and  Figure  20B).  In  contrast,  we  found  a  significant  increase  of 
JAM-C expression in the liver and the lung of pHHNS-JAM-C mice by 
Western blot (Figure 20B). However, in both organs the relative mass 
of endothelial cells is much higher than in the pancreas. 
These results indicate that JAM-C seems to be upregulated in pHHNS-
JAM-C  transgenic  mice  compared  with  control  mice  as  clearly 
demonstrated by immunohistochemistry. However, this increase is not 
detectable in whole pancreatic tissue lysates by Western blot analysis. 
 
Figure 20: Characterization of JAM-C expression in the pancreas of pHHNS-JAM-C 
transgenic mice. 
(A) Immmunofluorescence staining of pancreas sections of pHHNS-JAM-C transgenic mice (tg) 
compared to control mice (wt) (JAM-C, green; CD31, red). (B) Western blot analysis of JAM-C 
overexpression from total tissue lysates obtained from liver (Li), lung (Lu) and pancreas (P). 
Mean ± SEM of four different Western blot analysis of two mice each. Note that no significant 
upregulation of JAM-C expression was detectable even at day 10 after LCMV-infection. 
8.2.6  JAM-C  overexpression:  Virus-induced 
diabetes is not accelerated 
Previously we could show that blocking  of JAM-C with a neutralizing 
antibody  partially  reduced  T1D.  To  further  analyze  the  influence  of   83
JAM-C  the  pHHNS-JAM-C  transgenic  mice  overexpressing  JAM-C  on 
endothelial  cells  were  crossed  with  RIP-LCMV-GP  and  RIP-LCMV-NP 
mice.  In  the  RIP-LCMV-GP  lines  all  mice  turned  diabetic  in  a  highly 
synchronized  fashion  between  day  12  and  15  approximately  60  to 
80%  of  all  mice  developed  T1D  regardless  of  the  transgenic  JAM-C 
expression (Figure 21A). The development of disease in male, single 
transgenic RIP-LCMV-NP mice followed a similar pattern as seen in RIP-
LCMV-GP mice (Figure 21B), whereas the single transgenic RIP-LCMV-
NP females turned diabetic within the expected time range of 2 to 5 
months (Figure 21C). However, the kinetics and incidence of T1D was 
similar in double transgenic RIP-LCMV-NP x pHHNS-JAM-C mice (Figure 
21C). 
In  summary,  we  observed  that  upregulated  endothelial  JAM-C 
expression did not have any effect on LCMV-induced T1D neither in the 
fast-onset RIP-LCMV-GP line (Figure 21A) nor in the slow-onset RIP-
LCMV-NP  line  (Figure  21B  and  C).  Thus,  it  appears  that  increased 
endothelial JAM-C expression cannot accelerate the severity of disease. 
8.2.7  JAM-C  overexpression:  No  influence  on  islet 
infiltration,  viral  clearance  or  the  presence 
of LCMV-specific T cells 
In order to confirm that increased JAM-C expression has only a minor 
effect on the immunopathology of virus-induced diabetes, mechanistic 
evaluations were performed. First, the cellular infiltration into islets of 
Langerhans was analyzed. Pancreata of RIP-LCMV-GP x pHHNS-JAM-C 
and RIP-LCMV-GP mice were harvested at day 6 after i.p. infection of 1 
x 104 pfu LCMV and stained with Hämatoxylin.   84
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Figure 21: JAM-C overexpression does not influence the outcome of T1D. 
(A-C) Mean blood glucose levels (left panels) and diabetes incidence (right panels) of single 
transgenic RIP-LCMV and double transgenic RIP-LCMV x pHHNSﾖ–JAM-C mice that were infected 
with a single  dose  of LCMV. Blood glucose was measured at weekly intervals (values >300 
mg/dl were considered diabetic). Data are the mean ± SEM of 9-26 mice per group. (A) RIP-
LCMV-GP x pHHNSﾖ–JAM-C transgenic mice. (B) Male RIP-LCMV-NP x pHHNSﾖ–JAM-C transgenic 
mice. (C) Female RIP-LCMV-NP x pHHNSﾖ–JAM-C transgenic mice. 
At early time after infection, islets from both groups showed only small 
numbers of infiltrating lymphocytes and no significant differences were 
found  between  RIP-LCMV-GP  x  pHHNS-JAM-C  and  RIP-LCMV-GP  mice 
(Figure 22A). Second, spleens as well as pancreata from RIP-LCMV-GP 
x pHHNS-JAM-C and RIP-LCMV-GP mice were harvested at day 3, 7, and   85
14 after i.p. infection of 1 x 104 pfu LCMV to analyze the influence of 
JAM-C  overexpression  on  viral  clearance.  By  LCMV-plaque  assay  the 
highest viral titer in the pancreas and the spleen was found at day 3 
post-infection, whereas by day 14 after LCMV-infection no virus was 
detected in all organs analyzed. Importantly, no significant differences 
in clearance of LCMV in pancreas and spleen of RIP-LCMV-GP x pHHNS-
JAM-C and RIP-LCMV-GP mice was found on days 3, 7 and 14  post 
LCMV-infection  (Figure  22B).  Third,  Intracellular  cytokine  staining 
(ICCS) revealed no significant difference in IFN- positive CD8+ T cells in 
the spleen or in the PDLN of RIP-LCMV-GP x pHHNS-JAM-C compared to 
RIP-LCMV-GP  mice  at  day  10  after  LCMV-infection  (Figure  22C).  In 
both  mouse  groups  analyzed  approximately  2%  of  all  CD8+  T  cells 
isolated  from  the  PDLN  and  approximately  10%  of  all  CD8+  T  cells 
isolated from the spleen produced IFN- upon ex vivo stimulation with 
the GP33 peptide. These results confirm the previous findings showing 
no acceleration in the development of T1D in RIP-LCMV x pHHNS-JAM-
C  mice.  Thus,  constitutive  endothelial  overexpression  of  JAM-C 
expression  does  not  exacerbate  the  immunpathological  mechanisms 
leading to virus-induced diabetes in RIP-LCMV mice.   86
 
Figure 22: Increased JAM-C expression has no influence on islet infiltration, viral 
clearance or antigen specific immune response. 
(A)  Pancreas  sections  of  RIP-LCMV-GP  x  pHHNSﾖ–JAM-C  transgenic  mice  were  probed  for 
Hämatoxylin.  Insulitis  score  obtained  from  sections  of  3  mice  per  group  (n=40,  islets 
analyzed).  Scoring  system:  0,  no  infiltration;  1,  some  peri-insular  infiltration;  2,  heavy  peri-
insular infiltration with some intra-insular infiltrates;  3,  heavy  intra-insular  infiltration  and/or 
islet scars. (B) Virus titers in the pancreas (P) and spleen (SP) on days 3, 7 and 14 after 
infection are shown. Data are the mean ± SD of 3-4 mice per group. Det limit: Minimal number 
of plaques at highest tissue homogenate concentration required for statistical evaluation. (C) 
The presence of GP33-specific CD8+ T cells on day 10 after LCMV-infection in the spleen and 
PDLN of RIP-LCMV-GP or RIP-LCMV-GP x pHHNS-JAM-C mice was analyzed by ICCS (IFN-) after 
o/n in vitro stimulation with GP33 peptide. Data are the mean ± SEM of six mice per group.   87
D I S C U S S I O N   88
9 Discussion 
9.1  Attraction and transmigration in T1D 
Type  1  diabetes  is  a  chronic  T  cell-driven  autoimmune  disease  that 
causes  specific  destruction  of  pancreatic  ß  cells  in  genetically 
predisposed  individuals.  The  underlying  mechanisms  by  which  the 
antigen-specific  T  cells  migrate,  penetrate  and  transmigrate  through 
the endothelial cells surrounding the islets is still not fully understood. 
In my project I have analyzed different factors involved in attraction 
and diabedesis of leukocytes and give new insights into the complex 
network  of  chemokines  and  their  receptors  and  adhesion  molecules 
expressed on endothelial cells. 
9.2  Inhibition  of  CXCR3  receptor  with  an 
CXCR3  antagonist  and  its  influence  on 
T1D 
Previous studies have reported the importance of the CXCR3 receptor 
in  various  animal  models  of  chronic  autoimmune  diseases  such  as 
adjuvant  arthritis  in  rats,  murine  lupus  nephritis  and  experimental 
autoimmune  encephalomyelitis  (EAE)  (93-95).  Moreover,  in  another 
study from Frigerio et al., they have shown a delay in virus-induced 
T1D in CXCR3-/- RIP-LCMV-GP mice (60). In the present project we also 
used the RIP-LCMV mouse model as a model for human T1D that has 
been  useful  to  help  understand  the  pathogenic  processes  of  the 
disease.  In  addition,  we  blocked  the  CXCR3  receptor  with  a  CXCR3 
antagonist  called  NIBR2130.  Blocking  with  a  low-molecular  weight 
antagonist  is  of  high  pharmacological  interest  because  of  their  high   89
bioavailability,  their  safety  profile,  their  high  stability  and  especially 
because of the possibility to apply them orally unlike antibodies that 
have  to  be  administered  by  i.v. i n j e c t i o n .  T h e  c o m p o u n d  N I B R 2 1 3 0  
that is related to lysergic acid diethylamine (LSD) is highly specific for 
the CXCR3 receptor and inhibits the receptor with an IC50 value of 54 
nM  (91).  Moreover,  NIBR2130  does  not  inhibit  other  chemokine 
receptors such as CCR5, CXCR4 and CXCR2. Contrary to LSD it only 
inhibits  serotonin  5HT2A  receptor  with  an  IC50 v a l u e  b e l o w  1  µ M ,  
whereas  LSD  efficiently  binds  to  various  serotonin,  dopamine  and 
adrenergic receptors (91). The CXCR3 antagonist NIBR2130 binds to 
the  CXCR3  receptor  without  inducing  functional  activity.  In  a  study 
from  Zerwes  et  al.,  they  illustrated  by  a  CXCL11-induced  CXCR3 
receptor  occupancy  assay  in  rat  whole  blood  that  NIBR2130  indeed 
inhibited the CXCR3 receptor and that the receptor remained on the 
surface and was not internalized after binding of NIBR2130 (61). Due 
to these facts NIBR2130 is a highly selective and potent antagonist for 
the CXCR3 receptor and therefore a very promising structure useful as 
a drug to reduce leukocyte migration to the site of injury in several 
diseases. 
In  this  part  of  my  project  we  blocked  the  CXCR3  receptor  with 
NIBR2130  by  subcutaneously  implanted  osmotic  pumps  during  the 
development of T1D in the fast-onset RIP-LCMV-GP as well as in the 
slow-onset RIP-LCMV-NP mouse model. We found that the delivery of 
the antagonist was fully maintained and the blood concentration was 
always  kept  3  to  6  times  higher  than  the  IC50-value  during  the  first 
month,  which  includes  the  time  of  viral  infection  and  first  part  of 
antigen-specific  response  development  followed  by  autoimmune 
disease. Nevertheless, it seems that only a continuous delivery of the 
CXCR3 antagonist lead to the inhibition of the development of virus-  90
induced  T1D.  As  soon  as  the  administration  was  stopped  after  one 
month of treatment the mice rapidly caught up to the control animals 
in  terms  of  their  blood  glucose  levels  and  started  to  develop  the 
disease. In particular, we found a significant delay in the development 
of T1D in the slow-onset RIP-LCMV-NP strain but not in the fast-onset 
RIP-LCMV-GP  strain.  The  data  suggest  that  the  inhibition  of  CXCR3 
leads  to  a  significant  delay  in  the  onset  of  disease  but  is  not  that 
efficient to fully reduce T1D. Further, the more aggressive progress of 
T1D in the fast-onset RIP-LCMV-GP mice seems to be more resistant to 
CXCR3-blockade. Unexpectedly, the pathogenic processes of T1D, as 
reflected by islet infiltration of different T cell subsets did not differ in 
antagonist-treated  compared  to  buffer  treated  RIP-LCMV-NP  mice 
infected  with  LCMV.  We  have  only  detected  a  tendency  of  more 
activated antigen-specific T cells during  viral response in the control 
mice  compared  to  NIBR2130-treated  animals,  whereas  during  the 
development of autoimmunity equal amounts of antigen-specific T cells 
regardless  of  the  inhibition  of  the  CXCR3/CXCL10  interaction  was 
found. The distinct outcome of disease in the different mouse strains 
could be due to the fact that RIP-LCMV-GP mice develop T1D in a very 
rapid fashion with the presence of high affinity, autoaggressive CD8+ T 
cells  independently  of  CD4+ T  c e l l  h e l p .  A l t h o u g h  i t  i s  k n o w n  t h a t  
CXCR3 is predominantly expressed on TH1-polarized activated/memory 
T cells (58) it has been shown that 95% of LCMV-specific CD8+ T cells 
are CXCR3+ a f t e r  L C M V - i n f e c t i o n  ( 5 7 ) .  D i f f e r e n t  o u t c o m e  o f  T 1 D  i n  
these two mouse strains was observed in other studies as well where 
CXCL10 was specifically overexpressed by ß cells of Langerhans. In this 
study only in the RIP-LCMV-NP mice the development of disease was 
massively  accelerated  whereas  in  the  more  aggressive  RIP-LCMV-GP 
mouse model no influence of CXCL10 overexpression was found (57).   91
The  delay  in  the  onset  of  T1D  could  not  be  confirmed  by  the 
pathogenic mechanisms analyzed at day 28 after LCMV-infection. Islet 
infiltration  was  similar  and  the  functional  impairment  of  ß  cells  was 
comparable between NIBR2130-treated and untreated mice. Although 
the  CXCR3-receptor  was  blocked  in  NIBR2130-treated  mice  similar 
numbers  of  CXCR3+ l e u k o c y t e s  i n f i l t r a t i n g  i s l e t s  w e r e  f o u n d  w h e n  
compared to control animals. Since no difference in the infiltration rate 
of  aggressive  T  cells  within  the  pancreas  was  observed  the  islet 
infiltration of Tregs was analyzed. However, we did not find any increase 
of infiltrating Tregs, whose could favor the immunomodulatory processes 
and finally delaying the onset of T1D. 
Thus the only difference that was found between LCMV-infected RIP-
LCMV-NP  mice  that  have  been  treated with  NIBR2130  or  not  was  a 
minimal reduction in LCMV-specific CD8+ T cells at day 7 but not at day 
28 post-infection. Previously, it has been shown that the CXCR3-ligand, 
CXCL10  is  upregulated  at  days  1  to  4  after  LCMV-infection  (56). 
Moreover,  neutralization  of  CXCL10  resulted  in  decreased  islet 
infiltration,  preserved  insulin  production  and  abrogated  the 
development  of  T1D.  Among  the  expression  of  several  chemokines 
analyzed  at  different  time  points  after  LCMV-infection,  CCL5  in 
contrast to CXCL10 peaked at day 7 and 10 post-infection (56). CCL5 
has  been  shown  to  interact  with  CCR5  and  play  an  active  role  in 
recruiting leukocytes into inflammatory sites of injury (96). Since CCL5 
expression is upregulated after the peak of CXCL10 one could assume 
that  the  role  of  CXCR3/CXCL10  interaction  could  be  overtaken  by 
other chemokine receptor/ligand interaction at later time points after 
LCMV-infection. Therefore, a slight reduction in LCMV-specific T cells 
was observed at day 7 but not at day 28 after infection.   92
For blood glucose values to reach diabetic levels up to 80%-90% of all 
ß  cells  would  have  to  be  destroyed.  Thus,  at  day  28  after  LCMV-
infection the discordance between islet infiltration and blood glucose 
values  may  be  due  to  the  fact  that  in  control  mice  the  -cell 
destruction  threshold  has  already  been  reached.  In  the  NIBR2130-
treated  mice  only  60%-70%  of  all  ß  cells  might  be  destroyed  and 
therefore the mice range marginal underneath the threshold needed to 
develop T1D. 
In the study from Frigerio et al., besides the delay of T1D in CXCR3-/- 
RIP-LCMV-GP  mice  they  also  observed  more  CD3+  T  cells  infiltrating 
islets of control mice compared to CXCR3-/- mice at day 6 and 8 after 
LCMV-infection (60), which is in discordance to our findings. However, 
they used the fast-onset RIP-LCMV-GP mouse line developed in the lab 
of  Hengartner  and  Zinkernagel  (38)  and  a  different  LCMV  strain  for 
disease initiation. 
Nevertheless, the fact that there were still some infiltrations observed 
in absence of this CXCR3 receptor indicates that alternative routes of 
migration might lead to islet infiltrations. In another study the blockade 
of CXCR3 by NIBR2130 in a rat model of cardiac allograft rejection was 
analyzed. They found that the pharmacologic blockade did not result in 
prolonged cardiac allograft survival (61). Moreover, in another study 
antagonists  to  CXCR3  and  CXCR4  were  used  in  the  experimental 
autoimmune encephalomyelitis. There the blockade of both receptors 
simultaneously  significantly  inhibited  clinical  EAE  and  were  more 
beneficial than blocking both separately (95). Such data indicate that 
treatment of more than one critical player involved in the pathogenic 
processes of T1D would possibly be more successful in reducing the 
outcome of disease. One of such possible critical players might be the 
adhesion molecule JAM-C (see chapter: JAM-C and its role in T1D).   93
 
Figure  23:  Influence  of  NIBR2130  on  the  immunological  mechanisms  in  the  RIP-
LCMV mouse model. 
The neutralization of CXCR3 with NIBR2130 delays the development of T1D in the slow-onset 
of T1D mouse model. However, the blockade of CXCR3 has no influence on islet infiltration of 
CXCR3+ T  cells, CD8+ T c e lls a s  w e ll a s  T regs  after  one  month  of  LCMV-infection.  Moreover, 
NIBR2130-treatment has no impact on LCMV-specific T cells and the functional impairment of 
ß cells. 
Conclusion ﾖ– Project 1: 
In summary, I have found that pharmacologic blockade of CXCR3 during 
development of virus-induced T1D results in a moderate but significant 
delay of overt disease as long as CXCR3 remains blocked. However, the 
immunopathogenesis of T1D seems not be blocked since neither the 
frequency  nor  the  migratory  properties  of  islet-specific  T  cells  was 
significantly  changed  during  CXCR3  blockade.  These  results  suggest 
that it might need therapeutic interference that targets more than just 
one factor in the complex network of chemokine and cytokine signaling   94
to  prevent  aggressive  T  cells  to  reach  their  target.  The  moderate 
differences  in  the  onset  of  clinical  disease  during  CXCR3  blockade 
reflect  the  complex  pathogenesis  of  T1D.  Further,  our  findings 
underline  the  importance  of  possible  thresholds  in  the  number  of 
aggressive T cells and in the degree of -cell destruction that have to 
be reached for the occurrence of overt disease. 
9.3  JAM-C and its role in T1D 
In this part of my project we addressed the question whether JAM-C is 
involved in leukocyte transmigration to the site of injury in T1D. For 
this  purpose,  we  blocked  or  overexpressed  JAM-C  in  the  RIP-LCMV 
mouse  model.  The  blockade  of  JAM-C  with  a  neutralizing  antibody 
resulted  in  a  slight  reversion  or  delay  of  the  development  of  virus-
induced  diabetes  whereas  the  overexpression  of  JAM-C  had  no 
influence on the trafficking and transmigration of leukocytes to the ß 
cells of Langerhans. 
Leukocyte migration from the blood into tissue involves several steps 
of  molecular  interactions  between  leukocyte  and  endothelial  cells. 
These  interactions  allow  the  leukocytes  to  role,  adhere  and  finally 
transmigrate through the endothelial cells to the site of injury (66). 
JAM-C,  localized  in endothelial-cell  tight  junctions,  was  shown  to  be 
involved  in  the  final  steps,  namely  transmigration.  Previous  studies 
have  shown  that  JAM-C  plays  an  important  role  in  inflammatory 
pathologies such as peritonitis, arthritis and pancreatitis. Blockade of 
JAM-C  with  a  neutralizing  antibody  reduced  the  accumulation  of 
leukocytes at the site of inflammation (85, 86, 89). 
As shown in cerulein-induced pancreatitis in mice JAM-C is expressed 
within the pancreas and upregulated after cerulein treatment (89). In   95
our  investigations  we  found  JAM-C  expression  around  the  islets  of 
Langerhans as well as throughout the whole pancreas. Moreover, after 
LCMV-infection JAM-C expression was significantly upregulated at day 
10  to  14  and  correlated  with  the  islet  infiltration  and  functional 
impairment  that  prompt  to  the assumption  that  JAM-C may  play an 
important role in T1D. 
The  anti-JAM-C  antibody  used  inhibits  both  JAM-C  homophilic 
interactions as well as JAM-C/JAM-B heterophilic interactions (79). The 
blockade of JAM-C with this neutralizing antibody resulted in a slight 
delay in RIP-LCMV-NP mice. However, neither the infiltration rate nor 
the  presence  of  antigen-specific  T  cells  was  reduced  in  anti-JAM-C 
antibody-treated  mice at  day  7  and  28  after  LCMV-infection.  These 
results are consistent with a previous study using neutrophils, which 
demonstrated adhesion and transmigration on cultured HUVECs under 
flow was JAM-C independent (97). It has to be mentioned that this was 
an  in  vitro  study  and  that  in  different  experimental  models  of 
inflammation in mice an influence of JAM-C on leukocyte extravasation 
was shown (84, 86, 92). 
Further, in the more aggressive fast-onset RIP-LCMV-GP mouse model 
a reversion of the outcome of T1D was observed. As assessed in a 
previous  study  blocking  JAM-C  with  the  same  JAM-C  neutralizing 
antibody  did  not  affect  monocyte  transendothelial  migration  under 
flow, but led to increased monocyte reverse transmigration and return 
to the circulation (88). This observation raises the possibility that the 
disruption of the JAM-B/JAM-C interaction might lead to a shift in the 
leukocyte  entry/exit  equilibrium  at  endothelial  junctions.  Thus,  an 
increase of T cells with a reverse-transmigratory behavior might result 
in the observed reversion of T1D in some RIP-LCMV-GP mice.   96
The  influence  of  the  neutralization  of  JAM-C  in  a  peptide/adjuvant 
transfer  model  was  analyzed.  In  this  model  highly  reactive  P14 
splenocytes including GP33-specific CD8+ T cells were transferred prior 
diabetes induction with the stimulation of the immunodominant LCMV 
peptide  GP33 a n d  P o l y ( I : C ) .  I n  t h i s  m o d e l  J A M - C  b l o c k a d e  d i d  n o t  
diminish CD8+ T cell extravasation in vivo as analyzed by two-photon 
microscopy at day 7 to 9 after adoptive transfer of P14 splenocytes. 
Visualization  of  the  interaction  of  infiltrating  cells  and  ß  cells  within 
islets  demonstrated  a  highly  diverse  migration  behavior  of  individual 
cells. However, no difference between anti-JAM-C antibody-treated and 
control animals could be observed. This finding is possibly due to the 
overwhelming  number  of  transferred  highly  aggressive  GP33-specific 
CD8+ T cells. JAM-C blockade might therefore not be efficient enough 
to influence T1D in such an aggressive P14-transfer RIP-LCMV model. 
In  comparison  to  the  LCMV-infected  RIP-LCMV-GP  mice,  in  the  P14-
transfer  RIP-LCMV  model  the immune  response  was  characterized at 
day 7-8 after adoptive transfer. It is possible that the neutralization of 
JAM-C  has  similar  effect  after  the  initial  inflammation  as  in  the  RIP-
LCMV-GP mice. In those mice the neutralization of JAM-C resulted in a 
reversion  of  the  development  of  T1D  after  two  months  of  LCMV-
infection (Figure 24). 
JAM-C overexpression on mouse endothelial cells has been shown to 
increase the early influx of inflammatory cells into lungs after i.p. LPS 
challenge (92) and upregulate leukocyte infiltrate and tissue damage in 
cerulein-induced pancreatitis (89). In contrast, in our mouse model for 
T1D  JAM-C  overexpression  had  no  influence  on  the  development  of 
disease. Early infiltration, viral clearance as well as presence of antigen-
specific T cells were similar in double transgenic JAM-C x RIP-LCMV and 
in single transgenic RIP-LCMV mice.   97
 
Figure  24:  Influence  of  anti-JAM-C  antibody  treatment  on  the 
immunopathological mechanisms in the RIP-LCMV mouse model. 
The  blockade  of  JAM-C  with  a  neutralizing  antibody  results  in  a  slight  reversion  of  the 
development of T1D in RIP-LCMV-GP mice and slightly delays the onset of disease in the RIP-
LCMV-NP mice. However, the neutralization of JAM-C has no influence on islet infiltration and 
insulin production nor on LCMV-specific T cells. 
One  reason  for  the  contrary  findings  might  be  the  nature  of  the 
different  disease  model  used.  In  the  cerulein-induced  pancreatitic 
model  an  inflammation  within  the  acinar  part  of  the  pancreas  was 
induced by the administration of the chemical compound, cerulein that 
finally  resulted  in  pancreatitis.  Hence,  the  cerulein  model  is  rather 
different  than  the  virus-induced  RIP-LCMV  model  and  its 
immunopathogenic processes involved in the destruction of ß cells. An 
alternative explanation would be that JAM-C overexpression does not 
have any influence  on  virus-induced  T1D  because  unlike  to antibody 
treatment  JAM-C  is  overexpressed  from  the  beginning  of  the   98
development  and  therefore  the  immune  system  might  adapt  to  this 
exceptional condition. Further, we found that in contrast to cerulein-
administration  infection  with  LCMV  by  itself  induces  JAM-C 
upregulation  in  the  pancreas  at  the  time  of  peak  lymphocyte 
infiltration. Therefore, the additional transgenic overexpression might 
not have an accelerating effect on the migration of aggressive, islet-
specific T cells into the islets. In consideration of the fact that JAM-C 
overexpression  has  an  influence  on  leukocyte  infiltration  in  different 
inflammatory models such as the peritonitis model and the model of 
pulmonary leukocyte recruitment (92), JAM-C may not play such an 
important  role  during  the  development  of  T1D.  Moreover,  JAM-C 
expression  is  strong  in  the  respiratory  tract,  which  is  heavily 
vascularized and has a high endothelial cell content. Thus, in the lung 
JAM-C  plays  a  more  crucial  role  in  the  transmigration  of  leukocytes 
through the endothelial cell layer to penetrate the site of inflammation 
(Figure 25). 
There is evidence from several studies that adhesion molecules other 
than JAM-C indeed have an impact on the development of T1D. In an 
adoptive transfer model of diabetes in NOD mice the neutralization of 
L-selectin  or  VLA-4  that  are  expressed on  migrating  leukocytes  and 
interact  with  adhesion  molecules  expressed  on  the  endothelial  cells 
resulted in a reduction of T1D (68, 69). Moreover, the treatment with 
an  antibody  neutralizing  VCAM-1  delayed  the  onset  of  disease, 
whereas blocking antibody against ICAM-1 had only a marginal effect 
on the onset of T1D (71). ICAM-1 is constitutively expressed in low 
concentrations  on  endothelial  cells,  however  upon  inflammation  it  is 
highly  upregulated,  can  bind  LFA-1  and  MAC-1.  VCAM-1  plays  an 
important role in rolling arrest and firm adhesion. In contrast to ICAM-
1,  VCAM-1  is  only  expressed  on  endothelial  cells  after  cytokine   99
stimulation, binds to  VLA-4 and mediates adhesion of leukocytes to 
the endothelium (63, 67, 70). 
 
Figure  25:  Influence  of  JAM-C  overexpression  on  the  immunopathological 
mechanisms in the RIP-LCMV mouse model. 
The overexpression of JAM-C has no influence on the development of T1D in the RIP-LCMV 
mouse model. Moreover, the JAM-C overexpression has no impact on islet infiltration and viral 
clearance nor on LCMV-specific T cells. 
These data indicate that the interaction of VLA-4/VCAM-1 seems to 
be  crucial  for  the  rolling  and  adhesion  of  leukocytes  to  the  site  of 
injury in this adoptive transfer model of diabetes in NOD mice and the 
MAC-1 or LFA-1 interaction with ICAM-1 has less impact in this mouse 
model. Other than the adhesion molecules previously described JAM-C 
seems to play a minor role in rolling and adhesion of leukocytes. JAM-C 
is rather crucial in transmigration of leukocytes through the endothelial 
cell layer to enter the site of inflammation (84). JAM-C interacts with   100
MAC-1  and  CD11c  mediating  extravasation  of  leukocytes  (62,  79). 
Collectively these data and our findings in the RIP-LCMV model suggest 
that  JAM-C/MAC-1  interaction  plays  only  a  minor  role  in  the 
pathogenesis of T1D. 
Conclusion ﾖ– Project 2: 
Various studies have shown that JAM-C plays a pivotal role in several 
inflammatory pathologies. In this part of my project I investigated the 
influence of JAM-C in virus-induced T1D by several approaches such as 
neutralization and overexpression of JAM-C in the RIP-LCMV model as 
well  as  blockade  of  JAM-C  in  a  peptide/adjuvant  transfer  model. 
Although  LCMV-infection  causes  a  significant  increase  of  JAM-C 
expression and JAM-C neutralization resulted in a decrease and partial 
reversal  of  disease,  we  detected  only  a  minor  impact  of  JAM-C  on 
frequency  and  migration  of  islet-specific  T  cells.  Therefore,  we 
conclude that JAM-C expression plays a minor role in this model of T1D 
and other adhesion molecules are likely to compensate for the lack of 
JAM-C availability during the pathogenesis of the disease.   101
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10  Material and Methods 
10.1  Source of Materials 
10.1.1 Plastic ware 
70 µm nylon cell strainer  BD Falcon; 352350 
One touch Ultra  Life Scan Inc.; 060-213-10A 
96-well V-bottom plates  Anicrin; 3911924 
Cell culture flasks (25, 75, 175 cm2)  Cellstar 
Coverslip  Menzel-gläser 
Cryomolds  Electron Microscopy science; 62352-30 
Cryotubes  Sarstedt; 72.379.002 
Eppendorf tubes  Eppendorf 
FACS-tubes  Biorad; 223-9390 
FACS-tubes  BD Falcon; 352052 
Falcon tubes (15, 50 ml)  Cellstar 
Heparin coated capillary  Fisher scientific; 02-668-10 
Mini-Osmotic-Pump (Model 2002)  Alzet; 10165-07 
Needles (23G, 27G, 30G)  BD Microlance 
Plastic pipets (5, 10, 25, 50 ml)  Corning INC 
PVDF Transfer Membrane  PolyScreen; NEF1002 
Sialin coated slides  Menzel-gläser; J1800AMN/ 
Sterile Filter (50, 250, 500 ml)  Millipore; SCGPU05RE 
Syringes (1 ml)  Terumo; BS-01T 
Syringes (3, 5, 10, 20 ml)  Braun 
Teststrips  Life Scan Inc.; 2943903 
Tissue culture dishes  Cellstar 
Tissue culture plates (6, 12, 24, 48, 96 
well) 
Cellstar 
10.1.2 Chemicals 
Acetic Acid  J.T. Baker; 6052 
Agarose  Sigma; A9539   103
Ammonium sulfate  Merck; 101211 
APS  Sigma; A3678 
Aquamount  Merck; 1.08562.0050 
Brefeldin A  Sigma; B6542 
Bromophenol blue  Roth; 512.1 
Chloroform  Riedel-de Haën; 32211 
Citrate acid  Applichem; 77-92-9 
Dc Protein assay 
Reagent A 
Reagent B 
Reagent S 
BioRad 
500-0113 
500-0114 
500-0115 
DEPC (Diethylpyrocarbonate)  Sigma; D5758 
Dextran, Texas Red, 70 kDa  Invitrogen; D-1864 
DMSO (Dimethylsulfoxide)  Sigma; D5879 
pBR328-Marker  Roth; X902.1 
DTT (1,4-Dithiothreit)  Roth; 6908.1 
ECF substrate  Amersham Bioscience; RPN 5785 
EDTA  AppliChem; A1103.1000 
Ethanol absolut  Riedel-de Haën; 24102 
Ethidium bromide  Sigma; E8751 
Ficoll-Paque PLUS  GE Healthcare; 17-1440-02 
Formaldehyde  Redel-de Haën; 33220 
Glucose  Merck; 104074 
Glycerol  Roth; 3783.1 
H2O2  Roth; 8070.1 
HCl  Riedel-de Haën; 30721 
Hematoxylin  AppliChem A4840.1000 
HEPES  Gibco; 15630 
Hyflo Super Cel medium  Sigma; 56678 
Immunofluore mounting Medium  ICN; 622701 
Isofluran  Abbott; B506 
Iso-Propanol  Prolabo; R11-36-67 
Ketamine/xylazine hydrochloride solution  Sigma; K113 
Kwik-Stop Styptic Powder  ARC laboratories 106012 
Methanol  Fluka; 65543   104
NaCl  J.T. Baker; 0278 
Na-N3  Roth; K305.1 
NH4Cl  Merck; 1.01145.0500 
N-Methyl-2-pyrrolidinon  Aldrich; 32,863-4 
Paraformaldehyde  Merck; 1.04005.1000 
Pen/Strep  Gibco; 15140 
Peroxidase substrate  Vector; SK-4100 
Polyethylene glycol 200 (PEG200)  Sigma; P3015-500G 
Potassium acetate  Merck; 1.04820.1000 
Protein Assay Standard 1  BioRad 500-0005 
Protein G Sepharose 4 Fast Flow  GE Healthcare; 17-0618-01 
Protease inhibitor tablet  Roche 
Rotiphorese  Gel  30  (30% 
Acrylamide/0.8% bis-acrylamide) 
Roth; 3029.1 
Saponin  Sigma; S7900 
SDS  Roth; 2326.2 
Skim milk powder  Töpfer Allgäu; 60226 
Sodium Pyruvate  Gibco; 11360 
TEMED  Roth; 2367.3 
Tissue-Tek OCT  Sakura; 4583 
Triethanolamine  Sigma; 90278 
Tri-Reagent  Sigma; T9424 
Tris-HCl  Roth; 4855.2 
Tris  Usb; 77514 
Triton X-100  Sigma; T8787 
Trypan blue  Sigma; T8154 
Tween-20  Sigma; P7949 
Ultroser HY and Ultroser SF  Life Sciences; 66029 
Xylene  Riedel-de Haën; 16446 
10.1.3 Composition  of  buffers,  solutions  and 
culture media 
0.5% Trypsin-EDTA  Gibco; 25300 
2x Laemmli sample buffer  20% v/v Upper gel buffer   105
20% v/v Glycerol 
4% SDS 
1.54% DTT 
bromophenol blue 
ABC  reagent  solution  (Peroxidase 
Substrate Kit DAB) 
5 ml ddH2O 
4 drops of DAB Stock solution 
2 drops of Hydrogen Peroxide Solution 
DEPC H2O  1% DEPC in ddH2O 
stir over night and autoclave 
DMEM + GlutaMax I  Gibco; 61965 
FACS fixation buffer  PBS 
0.1% PFA 
FACS PBS/saponin buffer  PBS 
1% FBS 
0.1% NaN3 
0.1% Saponin 
FACS PBS/staining buffer  PBS 
1% FBS 
0.1% NaN3 
FACS PFA/saponin buffer  PBS 
0.1% Saponin 
10 mM HEPES 
4% PFA 
FBS (Foetal bovine serum)  Biochrom AG; S0115 
Lower gel buffer  1.5 M Tris-HCl (pH 8.8) 
Autoclave 
NIBR2130 buffer  418 µl N-Methyl-2-pyrrolidinon 
418 µl 0.1 M HCl 
5.43 ml PEG200 
2.93 ml 0.9% NaCl-solution  
PBS  Gibco; 14190 
Proteinase K  10 mg/ml Proteinase K 
10 mM Tris-HCl (pH 7.5) 
Proteinase K buffer  ddH2O 
0.5% SDS 
10 mM NaCl 
50 mM Tris (pH 8) 
3 mM EDTA 
Red blood cell lysis buffer  0.83% NH4Cl in ddH2O   106
Sterile filtrated 
RIPA buffer  ddH2O 
40 mM Tris (pH 7.5) 
150 mM NaCl 
1% Triton X-100 
6 mM EDTA 
10% Glycerol 
1% Na-deoxycholate 
0.1% SDS 
RPMI 1640 + GlutaMax I  Gibco; 61870 
Running buffer  25 mM Tris 
192 mM Glycine 
0.1% SDS 
pH 8.3 
TAE buffer  40 mM Tris-Acetate 
1 mM EDTA 
Transfer buffer  1.44% Glycine 
0.3% Tris 
80% v/v ddH2O 
20% v/v MeOH 
Upper gel buffer  0.5 M Tris-HCl (pH 6.8) 
Autoclave 
10.1.4 Enzymes and proteins 
Collagenase P  Roche; 11 213 857 001 
DNase  Sigma; DN25 
M-MLV-reverse transcriptase  Promega; M1705 
Protease inhibitor cocktail tablets  Roche; 11 873 580 001 
Proteinase K  Carl Roth; 7528.1 
RNase OUT  Invitrogen; 10777-019 
RQ1 RNase-free DNase  Promega; M6101 
Superscript II reverse transcriptase  Invitrogen; 18064-022 
Taq-polimerase  Peqlab Biotechnologie GmbH; 01-1030 
10.1.5 Nucleotides and nucleic acids 
GP33 peptide   KAVYNFATM 
NP396 peptide  FQPQNGQFI   107
GP61 peptide  GLKGPDIYKGVYQFKSVEFD 
CpG  IDT; ODN1826 
GP F Primer  5ﾒ’ GGG AAA GGA GAA TCC TGG AC 3ﾒ’ 
GP R Primer  5ﾒ’ GCA ATC TGA CCT CTG CCT TC 3ﾒ’ 
NP F Primer  5ﾒ’ AAT CCA TGT AGG AGC GTT GG 3ﾒ’ 
NP R Primer  5ﾒ’ AAC AGC GAG GAC CTC TTG AA 3ﾒ’ 
JAM-C F Primer  5ﾒ’ GGG AAG TCG CAA AGT TGT GAG TT 3ﾒ’ 
JAM-C R Primer  5ﾒ’ TGC AGT GTT GCC GTC TTG CCT ACA G 3ﾒ’ 
dNTP  Peqlab; 20-2011 
Poly(I:C)  Sigma; P9582 
Random Primers  Fermentas; S0142 
10.1.6 Antibodies 
Antibodies used for FACS-staining 
APC-anti-mouse CD8a/Lyt-2 (Clone 53-6.7)  Southern Biotech; 1550-11 
APC-anti-mouse CD4/L3T4 (Clone GK 1.5)  Southern Biotech; 1540-11 
FITC-anti-mouse CD4/L3T4 (Clone GK 1.5)  Southern Biotech; 1540-02 
FITC-anti-mouse CD45R/B220 (RA3-6B2)  BD Pharmingen; 553088 
FITC-anti-mouse CD8a/Lyt-2 (Clone 53-6.7)  Southern Biotech; 1550-02 
PE-anti-mouse CD8 alpha (Clone KT15)  Serotec; MCA609PEB 
PE-anti-mouse CD4 (Clone YTS191.1)  Serotec; MCA1767PEB 
PE-anti-mouse CD11c (p150/90)  eBiosience; 12-0114-82 
PE-anti-mouse IFN- B D   P h a r m i n g e n ;   5 5 4 4 4 1 2  
PE-Cy5-anti-mouse CD8a/Lyt-2 (Clone 53-6.7)  Southern Biotech; 1550-16 
Streptavidin-APC  Southern Biotech; 7100-11M 
Antibodies used for Western Blot 
Goat anti-mouse IgG (H+L)-AP Conjugate  Bio-Rad; 170-6520 
Swine anti-goat IgG (H+L) Alk. Phos. conjugate  Invitrogen; G50008 
Goat anti-mouse JAM-C IgG  R&D Systems; AF1213 
Mouse anti-ß-actin  Sigma; A5441 
Antibodies used for Histology 
Rat anti-mouse CD4/L3T4 (Clone GK 1.5)  BD Pharmingen; 553043 
Rat anti-mouse CD45R/B220 (RA3-6B2)  BD Pharmingen; 553084 
Rat anti-mouse CD8a/Lyt-2 (Clone 53-6.7)  BD Pharmingen; 553027   108
Rat anti-mouse Foxp3  eBioscience; 14-5773 
Rat anti-mouse F4/80  Serotec; MCAP497 
Polyclonal guinea pig anti-swine insulin  DakoCytomation; A0564 
Rat anti-mouse CD31  BD Pharmingen; 557355 
Goat anti-mouse NKp46/NCR1  R&D Systems; AF2225 
Biotinylated anti-goat IgG (H+L)  Vector; BA-5000 
Biotinylated anti-guinea Pig IgG (H+L)  Vector; BA-7000 
Biotinylated anti-hamster IgG (H+L)  Vector; BA-9100 
Biotinylated anti-rabbit IgG (H+L)  Vector; BA-1000 
Biotinylated anti-rat IgG (H+L)  Vector; BA-4001 
Antibodies used for Plaque assay  
Rat antibody specific for LCMV (VLA-4)  (98) 
Peroxidase-conj. AffiniPure goat anti-rat IgG (H+L)  Jackson  ImmunoResearch 
Laboratories,  Inc.;  112-035-
033 
10.1.7 Kits 
Avidin/Biotin blocking Kit  Vector; SP-2001 
Peroxidase Substrate Kit DAB  Vector; SK-4100 
Quantitec SYBR Green PCR  Qiagen; 204143 
RNeasy Mini Kit  Quiagen; 74104 
Roti-Histokit  Roth; 6638.1 
Roti-Quant Protein assay  Roth; 
SlowFade Antifade Kit  Molecular Probs; S2828 
10.1.8 Cell lines 
Rat hybridoma cells for anti-JAM-C antibody production 
Rat hybridoma cells are Sp2/0 cells that were fused with splenocytes 
from  JAM-C  antibody  immunized  male  Fisher  rats  (78)  and  were 
originally  received  from  Prof.  Beat  A.  Imhof  from  the  University  of 
Geneva. The cells were grown in DMEM, 1% Ultroser HY and 0.1% FBS.   109
MC57 (mus musculus) cells for plaque assay 
MC57  cells  are  a  methylcholanthrene-induced  fibrosacroma  cell  line. 
The  cells  were  maintained  in  RPMI  1640  medium.  All  media  were 
supplemented  with  2  mM  L-glutamine  and  7%  (vol/vol)  fetal  calf 
serum. 
10.1.9 Virus 
LCMV-Armstrong (Arm) 
The  Armstrong  strain  of  LCMV,  clone  53b,  was  used  for  all 
experiments.  LCMV  was  plaque  puried  three  times  on  Vero  cells 
(ATCC  CCL-81),  and  stocks  were  prepared  by  a  single  passage  on 
hamster  kidney  broblast  cell  line  BHK-21  (ATCC  CCL-10,  American 
Type Culture Collection, Manassas, VA). 
10.1.10  Mouse strains 
Transgenic mice (H-2b x H-2d  [bxd]) with rat insulin promoter (RIP) 
fused to cDNA encoding the NP or GP of LCMV-Arm were made for 
direct  expression  of  LCMV  viral  proteins  by  pancreatic  ß  cells.  The 
transgenic  mice  were  generated  by  standard  microinjection  of 
C57BL/6J  fertilized  eggs  with  the  construct  containing  hybrid  DNA 
molecules (37, 99). 
The transgenic pHHNS-JAM-C mice were generated under the control 
of  the  endothelial  specic  promotor  Tie-2.  The  coding  region  for 
murine JAM-C was inserted in place of lacZ-SV40pA into pBSIISK-HHNS 
construct (92). 
RIP-LCMV-GP x pHHNS-JAM-C and RIP-LCMV-NP x pHHNS-JAM-C double-
transgenic  mouse  lines  were  generated  by  crossing  pHHNS-JAM-C 
single-transgenic  mice  to  RIP-LCMV-GP  or  RIP-LCMV-NP  single-
transgenic lines.   110
The  DsRed+ P 1 4  d o u b l e - t r a n s g e n i c  m o u s e  l i n e  w a s  g e n e r a t e d  b y  
crossing DsRed+ single-transgenic mice to P14-TCR specific for LCMV-
H-2Db single-transgenic line (100, 101). 
RIP-LCMV-GP x MIP-GFP double-transgenic mouse line was generated by 
crossing  RIP-LCMV-GP  single-transgenic  mice  to  MIP-GFP  single-
transgenic  line  that  has  ß  cells  genetically  tagged  with  the  green 
fluorescence protein (36, 38, 102). 
Wild-type C57BL/6 mice were purchased from the breeding colony of 
Harlan Netherlands. 
Experiments were carried out with age- and sex-matched animals kept 
under specific pathogen free (SPF) conditions and in accordance with 
German regulations. All animal experiments were approved by the local 
Ethics Animal Review Board (Darmstadt, Germany). 
10.2  Methods 
10.2.1 Cell biological methods 
10.2.1.1  Cultivation of cells 
Cells were cultured in plastic cell culture flasks (25, 75 or 175 cm2) at 
37°C (5% CO2, relative humidity 95%) with appropriate medium. 
Adherent cells were split when confluent. Medium was removed from 
the culture flask, the cellular monolayer was rinsed with 10 ml sterile 
PBS and the cells were incubated for 5ﾖ–10 minutes at 37°C in 3 ml of 
trypsin-EDTA  solution  to  detach  the  cells  from  the  plastic.  The 
detached cells were collected, and spun at 250 x g for five minutes. 
Finally the cells were resuspended in appropriate medium and split.   111
10.2.1.2  Freezing of cells 
A  freezing  container  was  pre-cooled  for  30  minutes  at  4°C.  The 
freezing medium was prepared containing 90% FBS and 10% DMSO. 
Cells were trypsinized, washed with PBS and centrifuged at 250 x g for 
five minutes. Cells were resuspended in 1 ml of pre-cooled freezing 
medium  and  1  ml  aliquots  were  transferred  into  cryotubes.  The 
aliquots were placed into the freezing container and transferred to -
70°C. The freezing containers ensure that the cell samples are cooled 
down to ﾖ–70°C at a rate of 1°C/min. After 48 hours, the cryotubes 
were transferred to the liquid nitrogen tank (ﾖ–196°C). 
10.2.1.3  Thawing of cells 
Cell aliquots were taken out of the liquid nitrogen tank and warmed 
immediately in a water bath (37°C) until cells started to thaw. 1 ml of 
warm medium was added and liquefied cells were transferred into a 15 
ml tube. This step was repeated until all cells were thawed. Cells were 
step-wise thawed to dilute the liquefied DMSO as fast as possible to 
avoid cell damage. After spun cells at 250 x g for five minutes fresh 
culture medium was added and the cells were checked for their viability 
by trypan blue stain. Cells were cultured in appropriate conditions and 
the following day the cells were evaluated for viability and density. 
10.2.1.4  Determining the density of a cell suspension 
The cellular density of a suspension was determined by mixing 10-20 
µl of the cell suspension with an equal volume of Trypan blue solution. 
The  cells  in  the  resulting  suspension  were  counted  directly  in  a 
Neubauer chamber using a microscope. Dead cells were identified by 
cytoplasmic  staining  with  Trypan  blue.  A  grid  at  the  bottom  of  the   112
chamber was used to count the cells and the cell density (cells per ml) 
was calculated with the following formula: 
Cellular density (cells/ml) = number of cells on the grid x dilution factor x 104 ml-1 
10.2.1.5  Isolation of pancreatic islet cells 
Islet  cells  were  isolated  by  injecting  3  ml  of  collagenase  P  solution 
((1.2  U/ml)  in  RPMI  w/o)  into  the  pancreas.  After  30  minutes 
incubation at 37°C the warm RPMI were removed and 10 ml of cold 
RPMI was added. The pancreas was disaggregated by shaking the tube 
for one minute and passed through a kitchen sieve into fresh 50 ml 
tube. Two pancreata were pooled and filled up with RPMI to 50 ml. The 
cells were settled down for 5 minutes on ice and then the medium was 
sucked  off  leaving  20  ml  in  the  bottom  of  the  tube.  This  step  was 
repeated once but the cells were settled down for 10 minutes and the 
medium was sucked off to 15 ml. After refilling the tube with PRMI the 
cell suspension was centrifuged at 1000 rpm for two minutes at room 
temperature  (RT).  The  pellet  was  resuspended  in  10  ml  Ficoll-Paque 
Plus and overlaid with 5 ml RPMI. The gradient was centrifuged at 2000 
rpm for 15 minutes at RT. After spin the islets were transferred in a 
new 50 ml tube, once washed and handpicked for further use. 
10.2.1.6  Isolation of splenocytes 
Spleen cells were isolated by squeezing the spleen through a 70 µm 
nylon cell strainer with a syringe plunger in 10 ml RPMI. With a pipette 
a single cell suspension was prepared in 10 ml RPMI. The supernatant 
was centrifuged at 1600 rpm for five minutes at 4°C. To eliminate the 
red blood cells the pellet was resuspended in 5 ml 0.83% NH4Cl in PBS 
and incubated for one to two minutes at RT. To stop the reaction 5 ml 
RPMI was added and the cells were centrifuged at 1600 rpm for five   113
minutes at 4°C. The cell pellet was resuspended in RPMI 10% FBS, P/S 
and the cells were kept at 4°C until use. 
10.2.1.7  Isolation of pancreatic lymphocytes 
Pancreatic  lymphocytes  were  isolated  by  mashing  the  pancreas 
between two slides and further squeezing the remaining tissue through 
a  70  µm  nylon  cell  strainer  with  a  syringe  plunger  in  10  ml  RPMI 
supplemented  with  0.1  mg/ml  DNase.  With  a  pipette  a  single  cell 
suspension  was  prepared  in  10  ml  RPMI.  The  cell  suspension  was 
centrifuged at 1600 rpm for five minutes at 4°C. The cell pellet was 
resuspended in RPMI 10% FBS, P/S and the cells were kept at 4°C until 
use. 
10.2.1.8  Isolation  of  lymphocytes  from  pancreatic  draining 
lymph nodes 
The  lymphocytes  from  the  pancreatic  draining  lymph  nodes  were 
isolated  by  squeezing  the  lymph  nodes  through  a  70  µm  nylon  cell 
strainer with a syringe plunger in 10 ml RPMI. With a pipette a single 
cell suspension was prepared in 10 ml RPMI. The cell suspension was 
centrifuged at 1600 rpm for five minutes at 4°C. The cell pellet was 
resuspended in RPMI 10% FBS, P/S and the cells were kept at 4°C until 
use. 
10.2.1.9  Preparation  of  protein  extraction  from  liver,  lung 
and pancreas homogenates 
Organs were harvested and homogenized with a tissue homogenizer in 
5 ml RIPA-buffer containing protease inhibitor.   114
10.2.1.10 Flow cytometry 
FACS staining of blood, spleen, pancreatic draining lymph nodes and 
pancreas 
Cells were harvested and centrifuged at 1600 rpm for five minutes. 
Erythrocytes  were  lysed  by  resuspending  the  cell  pellet  with  5  ml 
0.83% NH4Cl, wait for two minutes and adding 5 ml RPMI containing 
10% FBS to stop the reaction. Around 106 cells were transferred to a 
V-bottom 96-well plate. The cells were washed once by spinning the 
plate at 1600 rpm for five minutes at 4°C, resuspending with 150 µl 
FACS PBS/staining buffer and spinning again for five minutes. The cells 
were  stained  with  fluorocrome  labeled  antibody  of  choice  in  50  µl 
PBS/staining buffer for at least 20 minutes at 4°C in the dark. After 
two additional washes with 150 µl PBS/staining buffer the cells were 
fixed in 200 µl FACS-fixation buffer and transferred to FACS-tubes and 
analyzed by flow cytometry at a BD FACS Calibur or BD FACS Canto II. 
10.2.1.11 Intracellular cytokine stain (ICCS) 
Restimulation of lymphocytes 
Cytotoxic  T  lymphocytes  (CTLs)  produce  Interferon- ( I F N - )  after 
stimulation;  therefore  intracellular  staining  for  IFN- w a s  u s e d  t o  
quantify specific and functionally competent CTLs. 
100 l lymphocytes at 107 cells/ml in RPMI 10% FBS, P/S, 50 l of the 
specific  stimulant  (2  µg/ml  GP33,  NP396,  or  4  µg/ml  GP61)  and  50  l 
RPMI 10% FBS containing 2 g/ml Brefeldin A (to block secretion of 
IFN-) were added per well of a flat-bottom 96-well plate. Negative and 
positive controls were included adding 50 l of medium or  50  l of 
peptides  added  to  splenocytes  harvested  at  day  7  post  LCMV-
infection. The plate was incubated for six hours or overnight at 37°C,   115
5% CO2. The cells were resuspended and transferred to a 96-well V-
bottom plate and were ready for staining. 
Staining 
After  the  cells  were  washed  twice  by  resuspending  with  150  µl 
PBS/staining buffer and spinning at 1600 rpm for five minutes at 4°C 
the cells were stained with fluorocrome labeled anti-CD8 and/or anti-
CD4 antibody in 50 µl PBS/staining buffer for at least 20 minutes at 
4°C in the dark. After two additional washes with 150 µl PBS/staining 
buffer  the  cells  were  fixed  and  permeabilised  with  100  µl  of 
PFA/saponin  solution  for  10  minutes  at  RT.  After  the  cells  were 
washed  twice  by  resuspending  with  150  µl  PBS/saponin  buffer  and 
spinning at 1600 rpm for seven minutes at 4°C the cells were stained 
with  PE-conjugated  anti-mouse-IFN- a n t i b o d y  i n  5 0  µ l  P B S / s a p o n i n  
buffer for 30 minutes at 4°C in the dark. After washing the cells two 
times with PBS/saponin buffer and once with PBS/staining buffer the 
cells were resuspended in 200 µl FACS fixation buffer, transferred to 
FACS-tubes analyzed by flow cytometry. 
10.2.1.12 LCMV Plaque assay 
MC57 cells were grown in RPMI 1640, 7% FBS and were split 1:1 one 
day  before  starting  the  assay  to  have  the  cells  in  their  expansion 
phase. A cell suspension at a concentration of 8 * 105/ml was used. 5 
ml  of  this  cell  suspension  was  needed  for  each  24-well  plate.  The 
organs used were weighed prior freezing in liquid nitrogen. The organs 
were kept frozen at ﾖ– 80°C until further use. Organs were put into 1 ml 
MEM with 2% FBS per 0.1 g of tissue. After grinding the organs with a 
homogenizer the samples were centrifuged for 5 minutes at 300 x g 
and kept on ice until further use. 130 µl MEM with 2% FBS were added 
to rows 2-12 of a round bottom 96-well plate. After adding 200 µl of   116
sample in duplicate to the first row a 1:10 dilution was performed. 200 
µl  of  the  MC57  cells  were  added  to  a  24-well  plate and  200  µl  of 
diluted samples were transferred to the MC57 cells. After four hours 
incubation at 37°C, 5% CO2 400 µl of a 1:1 mixture of 2x DMEM and 
2% methyl cellulose was overlaid onto the cell ﾖ– organ sample mixture. 
After 2 days incubation at 37°C, 5% CO2 plates were stained with DAB 
substrate. After flicking of the overlay form the cells the cells were 
fixed  with  4%  formalin-PBS for  30  minutes  at  RT.  Then  240  µl  1% 
Triton X solution was added to each well and incubated for 20 minutes 
at RT. To block unspecific binding 240 µl 10% FBS in PBS was added 
and incubated for 1 hour at RT. 240 µl of 1:4 diluted VL-4 rat anti-
LCMV  antibody  in  1%  FBS  in  PBS  was  added  to  the  samples  and 
incubated for  60 minutes at RT.  After  washing the plate twice with 
PBS 240 µl 1:400 diluted second antibody in 1% FBS in PBS was added 
to each sample. After 60 minutes incubation at RT plates were washed 
twice with PBS and 300-400 µl of the DAB substrate was added to 
each  sample,  incubated  for  5-10  minutes,  until  a  good  color  was 
produced. The coloring was stopped by washing the plates with tap 
water.  Finally,  to  let  the  plates  dry  they  were  inverted  placed  on  a 
paper towel. The virus titer was calculated with the following formula 
(two adjacent wells were counted): 
Titer = ((m x 10) + n) /2 x (dilutionfactor of lower dilution) x 5 [pfu/ml] 
m = number of foci in the well with higher dilution (less foci) 
n = number of foci in the well with lower dilution (more foci) 
10.2.1.13 Anti-JAM-C antibody production and purification 
Rat hybridoma cells were grown in DMEM, 1% Ultroser HY and 0.1% 
FBS. The collected supernatants were filtered on Hyflo super cel and 
0.45 µm polycarbonate filter.   117
Then  the  supernatants  were  precipitated  with  45%  (277g/l)  of 
ammonium sulphate by adding the salt progressively over a period of 
two hours minimum at 4°C with agitation. After the precipitation the 
solution  was  centrifuged  at  3ﾒ’000  x  g  for  30  minutes  at  4°C.  The 
supernatant  was  discarded  and  the  precipitate  was  resuspended  in 
1/50 of the initial volume in PBS. After dialyses against PBS for 4-6 
hours the solution was centrifuged in Eppendorf tubes at 14ﾒ’000 rpm 
in  a  micro-centrifuge  to  remove  Transferrin.  The  supernatants  were 
collected and filtered on 0.22 µm filter. 
For the purification of the antibody Protein G sepharose 4 fast flow 
was used. Because the binding capacity of the resin is reduced for rat 
IgG,  approximately  2  mg/ml  of  gel  was  necessary.  The  amount  of 
needed Sepharose G slurry was washed once with PBS and centrifuged 
at 500 x g for five minutes and then the beads were settled down for 
10  minutes  more.  After  removing  the  supernatant  the  antibody 
solution was added to the beads and incubated over night at 4°C on an 
end-over-end  rotation.  The  beads  with bound  antibody  were  washed 
twice with PBS, centrifuged at 500 x g for five minutes and settled 
down  for  ten  minutes  more.  The  antibodies  were eluted  with  0.1  M 
Triethanolamine (pH 10.5). After removing the supernatant the same 
volume  of  Triethanolamine  as  the  bead  volume  was  added  and 
incubated for two minutes at RT and centrifuged at 500 x g for five 
minutes.  After  collecting  the  eluted  antibody  the  solution  was 
immediately  neutralized  with  2  M  Tris  pH  7.5.  The  elution  step  was 
repeated seven times. After the protein concentration was determined 
on  a  Nano-drop  (ND-1000  Spectrometer),  the  fractions  of  interest 
were pooled and salt exchanged against PBS for 4-6 hours. At the end 
the  antibody  concentration  was  measured  by  Nano-drop,  filtered  on 
0.22 µm filter and stored at 4 or ﾖ– 20°C until use.   118
10.2.1.14 Determination of NIBR2130 in mouse whole blood 
Before  analysis  whole  blood  samples  were  prepared  by  a  protein 
precipitation  step.  Calibrations  and  quality  control  samples  were 
prepared in mouse whole blood. For each calibration a 50 µl aliquot of 
unknown whole blood samples or control samples was transferred to 
0.5 ml Eppendorf tubes. 20 µl internal standard (a structurally related 
compound  with  similar  behavior)  at a  concentration  of  1  µg/ml  was 
added  to  each  sample, except  blank  samples.  After  short  mixing  by 
vortex 100 µl of 0.04 mol/l ZnSO4 in 90% methanol was added to each 
sample.  After  the  samples  were  ultrasonicated  for  10  minutes  and 
vortexed for 15 minutes they were centrifuged at 16ﾒ’000 x g for 5 
minutes. A 60 µl aliquot of the supernatant of each sample was diluted 
with 30 µl water in HPLC-µ Vials and stored at 10°C until analysis. For 
the chromatography 10 µl of each sample were directly injected on a 
Kromasil 100-C18 0.5 x 50 mm column with 3.5 µm particles (G&T 
Septech AS, Norway). The column was heated at 50°C. For separation 
a  linear  gradient  was  applied  (Table  1).  Solvent  A  was  0.2%  formic 
acid,  solvent  B  0.2%  formic  acid  in  acetonitrile  and  the  flow  of  the 
capillary pump was hold at 20 µl/min. 
Time (minutes)  Solvent B (%)   
0  5   
3.0  5  Switch to mass spectrometry 
10.0  95   
12.0  95  Switch to waste 
12.1  5   
15.0  5  Stop time 
Table 1: Gradient conditions for separation. 
For  detection,  the  column  effluent  was  directly  injected  into  the 
atmospheric pressure electrospray source (AP-ESI) of the linear trap   119
mass spectrometry with a capillary temperature of 250°C a sheet gas 
flow of 20 l/h and a auxiliary gas flow set to 10 l/h. Compound and 
internal standard were detected as their [MH]+ ions in MRM mode with 
a  spray  voltage  of  3.5  V  and  the  collision  energy  set  to  20%.  For 
detection  parameters  were  optimized  for  NIBR2130  and  the  mass 
transition  498.2  m/z   3 7 9 . 2  +  4 0 5 . 2  m / z ,  a p p l y i n g  a n  i s o l a t i o n  
window of 2 m/z, was used. 
10.2.1.15 Immunohistological stainings 
Immunohistochemical stainings 
Organs were harvested at the times indicated, immersed in Tissue-Tek 
OCT, and quick-frozen on dry ice. 6 - 7 µm tissue sections were cut 
using a cryomicrotome and mounted on sialin-coated slides. 
Three  different  fixing  types  were  used:  Sections  were  fixed  in  95% 
ethanol or 1:1 diluted ethanol/acetone at -20°C for 15 minutes and 
after drying the slides on a paper towel for ten minutes circles were 
drawn around the specimen with a wax pencil. In the third fixing type 
the circles were drawn around the specimen before fixation with 4% 
PFA at RT for 10 minutes. 
The  sections  were  washed  two  times  in  PBS  for  two  minutes  and 
incubated  in  0.3%  H2O2/0.1%  Na-azid  in  PBS  for  15  minutes  at  RT. 
After washing two times in PBS for two minutes one drop of avidin was 
placed  on  each  specimen  and  incubated  for  10  minutes  at  RT.  The 
sections  were  washed  and  one  drop  of  biotin  was  placed  on  each 
specimen  and  incubated  for  10  minutes  at  RT.  After  an  additional 
washing step, a few drops of 10% FBS in PBS was added and incubated 
for  15  minutes  at  RT.  The  10%  FBS  in  PBS  was  tapped  off,  the 
sections were washed quickly in PBS and ~ 60 µl of the first antibody 
diluted  1:200  ﾖ–  1:1000  in  10%  FBS  in  PBS  was  added  on  each   120
specimen and incubated for one hour at RT in a humidified chamber. 
After tapping off the first antibody solution, the sections were washed 
two times in PBS for four minutes and 100 µl of biotinylated secondary 
antibody  diluted  1:200  ﾖ–  1:1000  in  10%  FBS  in  PBS  was  added  on 
each  specimen  and  incubated  for  45  minutes  at  RT  in  a  humidified 
chamber. The secondary antibody solution was tapped off and sections 
were  washed  two  times  for  four  minutes  in  PBS.  One  drop  of  ABC 
reagent solution was added on each specimen and incubated for 30 
minutes at RT. After tapping off the remaining ABC reagent and two 
washes in PBS for four minutes 60 µl peroxidase substrate was added 
on each specimen and incubated for five minutes at RT. The reaction 
was stopped by washing in PBS and the sections were counterstained 
in hematoxylin solution for five minutes at RT and washed two times in 
PBS.  After  adding  two  drops  of  aquamount  onto  each  section  a 
coverslip was placed onto each slide. The sections were then incubated 
at RT for more than two hours and pictures were made at a Microscope 
(Biozero BZ-8000, Keyence). 
Immunofluorescence stainings 
Organs were harvested at the times indicated, immersed in Tissue-Tek 
OCT,  and  quick-frozen  on  dry  ice.  6-7  µm  tissue  sections  were  cut 
using  a  cryomicrotome  and  mounted  on  sialin-coated  slides.  After 
fixing the sections in 95% ethanol at -20°C for 15 minutes, or with 4% 
PFA, the sections were washed two times in PBS for two minutes and 
incubated for 30 minutes with PBS containing 10% FBS in PBS at RT. 
After tapping off the FBS in PBS blocking solution the sections were 
washed in PBS and the first antibody diluted 1:200 ﾖ– 1:1000 in FBS in 
PBS was added to the sections and incubated for two hours at RT in a 
humified  chamber  in  the  dark.  After  washing  three  times  in  PBS  for   121
four minutes the fluorescent-labeled secondary antibody diluted 1:200 
ﾖ– 1:400 in FBS in PBS was added and the sections were incubated for 
one  hour  at  RT  in  a  humidified  chamber  in  the  dark.  The  secondary 
antibody solution was tapped off and the sections were washed three 
times  in  PBS  for  four  minutes  and  then  mounted  in  immunofluore 
mounting medium. 
10.2.2 Molecular biological methods 
10.2.2.1  Mouse tail DNA isolation 
Tail biopsies (0.3 cm) were digested overnight with 5 µl of proteinase 
K (10 mg/ml) in 500 µl of proteinase K buffer at 55°C. 75 µl of 8M 
KOAc and 500 µl chloroform were added and the tubes were inverted 
several times, incubated at -70°C for 15 minutes and centrifuged for 
five  minutes  at  14ﾒ’000  rpm  in  a  micro-centrifuge.  Then  the 
supernatant was transferred to new tubes, 1 ml of ethanol was added 
and  the  tubes  were  inverted  several  times.  After  centrifugation  at 
14ﾒ’000  rpm  for  10  minutes  the  supernatant  was  removed  and  the 
DNA pellet was washed with 1 ml of 70% ethanol. DNA was air dried 
for 10 to 30 minutes and then re-dissolved in 100 µl TE buffer and 
stored at 4°C. 
10.2.2.2  RNA extraction from tissues 
Tissues were harvested and homogenized in 1 ml TRI reagent per 50-
100 mg tissue with a tissue homogenizer. Per 50-100 mg tissue 0.2 
ml chloroform was added and the homogenate was vortexed for 15-20 
seconds.  After  2-15  minutes  incubation  at  RT  the  homogenate  was 
centrifuged at 12ﾒ’000 x g for 15 minutes at 4°C. After centrifugation 
the upper aqueous phase was transferred into a new tube and 0.5 ml 
isopropanol  was  added.  The  tubes  were  inverted  several  times  and   122
after  an  incubation  of  5-10  minutes  centrifuged  at  12ﾒ’000  x  g  for 
eight minutes. The supernatant was removed and the RNA pellet was 
washed with 1 ml 75% ethanol. After centrifugation at 7ﾒ’500 x g for 
five minutes the RNA pellet was air dried for 5-10 minutes and then re-
dissolved in an appropriate volume of H2ODEPC and incubated at 56°C for 
ten minutes. The RNA concentration was determined on a Nano-drop 
(ND-1000 Spectrometer) and the RNA was stored at -80°C for further 
usage. 
10.2.2.3  Polymerase chain reaction (PCR) 
PCR was used to amplify the transgenic insert of the RIP-LCMV-GP, RIP-
LCMV-NP, and JAM-C mice for screening. 
The components of the PCR reaction: 
 N P ,  JAM-C  GP 
ddH2O  19.9 µl  14.3 µl 
10x PCR buffer  2.5 µl  2 µl 
10 mM dNTP-Mix  0.5 µl  1.6 µl 
10 µM reverse Primer  0.5 µl  0.5 µl 
10 µM forward Primer  0.5 µl  0.5 µl 
TAQ-Polymerase  0.1 µl  0.1 µl 
DNA  1 µl  1 µl 
Cycling: 
 G P   N P   J A M - C  
initial denaturation at   94°C > 3 min  94°C > 5 min  95°C > 1:30 min 
      
 3 5   c y c l e s :   3 5   c y c l e s :   4 0   c y c l e s :  
denaturation at   94°C > 45 sec  94°C > 30 sec  95°C > 30 sec 
primer annealing at   56°C > 45 sec  56°C > 30 sec  63°C > 30 sec 
elongation at   72°C > 1 min  72°C > 1 min  72°C > 1 min 
      
additional elongation at   72°C > 3 min  72°C > 3 min  72°C > 7 min   123
Cool to  4°C  4°C  4°C 
For all reactions a water sample was included as negative control to 
confirm the viability of the PCR result. PCR products were analyzed by 
agarose gel electrophoresis. 
10.2.2.4  DNA agarose gel electrophoresis 
Separation  of  DNA  fragments  of  different  sizes  was  achieved  by 
agarose gel electrophoresis. A 1% agarose gel was routinely used and 
the  expected  size  of  the  fragments  was  between  0.5  and  10  kb. 
Agarose was dissolved in TAE buffer by boiling. After cooling to hand 
temperature 1 µg/ml Ethidium bromide was added while stirring. The 
solution was poured into an appropriate gel tray with inserted combs. 
Following cooling and solidification the combs were removed and the 
gel was placed into an electrophoresis container containing 1x TAE as 
running buffer. The slots were loaded with DNA samples to which 16% 
of  6x  DNA  loading  dye  was  added.  An  appropriate  DNA  molecular 
weight  marker  was  run  in  parallel  in  order  to  evaluate  molecular 
weights of the DNA fragments. The voltage applied for the separation 
was 5V per cm space between the two electrodes. The gels were run 
for 20-30 minutes and the separated DNA bands were visualized and 
pictures were taken under UV irradiation (300 nm). 
10.2.2.5  Quantification of DNA, RNA and proteins 
DNA  and  RNA  concentrations  were  measured  on  a  Nano-drop  (ND-
1000 Spectrometer). 
Protein  concentrations  were  measured  with  two  different  assays 
dependent on the protein solution: First, the Bio-rad Protein assay and 
the standard protocol followed. In brief, 50 µl PBS and 50 µl protein 
sample were mixed and 2-fold serial diluted with PBS over 11 steps of   124
a 96-well flat bottom plate. The standard solution (2 mg/ml) was serial 
diluted 2-fold with PBS in duplicates and two wells were filled with 100 
µl PBS as blank controls. Color developer was diluted 1:5 in PBS, 200 µl 
were added to all wells and the plate was measured at 595 nm with an 
ELISA microplate reader (Sunrise, Tecan). 
Second,  the  Lowry  assay  (Bio-Rad  DC  Protein  Assay),  a  colorimetric 
assay  was  used  for  protein  concentration  in  detergent  solution.  In 
brief, 20 µl of samples and standards (0.2-1 mg/ml) were mixed with 
100 µl of reagent Aﾒ’ (20 µl of reagent S to each ml of reagent A). 800 
µl of reagent B was added to each sample, mixed and 250 µl of each 
mix were transferred to a 96-well flat bottom plate. RIPA-buffer was 
used  as  blank  controls.  After  15  minutes  at  RT  absorbance  was 
measured  at  650-750  nm  with  an  ELISA  microplate  reader  (Sunrise, 
Tecan). 
10.2.2.6  SDS PAGE 
For the separation of proteins, first an appropriate separating gel was 
prepared using a 0.75 mm spacer: 
 1 0 %     o n e   g e l   t w o   g e l s   1 2 %     o n e   g e l   t w o   g e l s  
Acrylamide  3.33 ml  5 ml  4 ml  6 ml 
Lower gel buffer  2.5 ml  3.75 ml  2.5 ml  3.75 ml 
Distilled water  4.07 ml  6.1 ml  3.4 ml  5.1 ml 
SDS (20% w/v)  50 µl   75 µl  50 µl  75 µl 
TEMED  5 µl  7.5 µl  5 µl  7.5 µl 
APS (10% w/v)  50 µl  75 µl  50 µl  75 µl 
Just  after  adding  the  TEMED  and  APS,  the  acrylamide  solution  was 
poured to about 5.3  cm from the bottom. During  polymerisation an 
isopropanol  or  water  overlay  was  added.  After  ~  one  hour  of   125
polymerisation  the  overlay  was  removed  and a  3%  stacking  gel  was 
prepared: 
 3 %     o n e   g e l   t w o   g e l s  
Acrylamide  0.5 ml  0.75 ml 
Upper gel buffer  1.25 ml  1.875 ml 
Distilled water  3.25 ml  4.875 ml 
SDS (20% w/v)  25 µl  37.5 µl 
TEMED  5 µl  7.5 µl 
APS (10% w/v)  25 µl  37.5 µl 
Immediately after pouring, the comb was added. Samples were heated 
for  5  minutes  to  95°C  in  2x  or  4x  Laemmli  sample  buffer.  After 
polymerization, the comb was removed and the wells were washed with 
1x Running buffer to remove any unpolymerised acrylamide. The gels 
were mounted in the electrophoresis apparatus and the inner chamber 
was filled with 1x Running  buffer. The samples were loaded and the 
outer chamber was also filled with 1x Running buffer. Electrophoresis 
was performed at 125ﾖ–140 V until the front reached the bottom of 
the gel (1-1.5 hours). 
10.2.2.7  Western blotting 
A PVDF membrane (5.2 x 8.5 cm) was prepared and put into methanol 
for five seconds. The membrane and four pieces of Whatman paper (6 
x 9 cm) were equilibrated in transfer buffer for five minutes. The gel 
and the membrane were put into the blotting apparatus together with 
the  Whatman  paper  in  the  following  order:  2  Whatman  paper  ﾖ– 
membrane  ﾖ–  gel  ﾖ–  2  Whatman  paper.  Air  bubbles  in  between  were 
removed by rolling a glass pipette over the stock. The proteins were 
blotted onto the membrane at constant 125 mA per gel, thus set at 
250 mA if transferred two gels. It was run for one and a half hours.   126
For blocking, the membrane was incubated for two hours at RT in PBS 
5% milk containing 0.1% Tween-20 on a shaker. The primary antibody 
was diluted 1:100-1:10ﾒ’000 in PBS 5% milk containing 0.1% Tween-
20. The membrane was incubated over night at 4°C together with 10 
ml of the antibody solution. After washing six times with PBS 5% milk 
containing  0.1%  Tween-20  for  five  minutes,  the  second  stage 
antibody, IgG was added at a dilution of 1:1000-1:20ﾒ’000 in 10 ml PBS 
5%  milk  containing  0.1%  Tween-20.  The  membrane  was  incubated 
together with this solution at RT for two hours, washed three times 
with PBS 5% milk containing 0.1% Tween-20 and another three times 
with PBS for five minutes. The separated protein bands were visualized 
with 1 ml ECF reagent and pictures were taken on a Pharos (Pharos FX 
Plus Molecular Imager, Bio Rad) 
10.2.3 Experiments with mice 
10.2.3.1  Blood collection 
Mice were anesthetized with isofluran and blood samples were taken 
retro-orbitally  with  a  heparin  coated  capillary.  In  an  eppendorf  tube 
100 µl blood was collected in 0.05 M EDTA to inhibit blood coagulation 
and  stored  at  -80°C.  Blood  was  collected  at  various  time  points  as 
indicated. 
10.2.3.2  Injections 
LCMV-Arm intraperitoneal injections (i.p.) 
Unless described otherwise, mice were injected with a total of 1 x 104 
particles of LCMV-Arm (i.p.). Mice were held in one hand and 100 µl 
virus were injected with a syringe intra peritoneal. 
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Anti-JAM-C antibody intraperitoneal injections (i.p.) 
Mice were injected with 100 µg anti-JAM-C antibody (i.p.). Mice were 
held in one hand and 100 µl antibody was injected with a syringe intra 
peritoneal one day before and then at days 1, 2, 5, 8, 11, and 14 after 
LCMV-infection in RIP-LCMV-GP mice and one day before and then at 
days 1, 3, 7, 11, 14, 18, 22, 26, 29, and 34 post LCMV-infection in 
RIP-LCMV-NP mice. 
TCR-transgenic P14 splenocytes intravenous injection (i.v.) 
Mice  were  injected  with a  total  of  1.5  x  107 D s R e d + T CR - t r a n sg e n i c  
P14 splenocytes (i.v.). Mice were anesthetized with isofluran and 200 
µl  of  DsRed+  TCR-transgenic  P14  splenocytes  were  injected  with  a 
syringe retro-orbitally. 
GP33 peptide, CpG and Poly(I:C) intraperitoneal injections (i.p.) 
One and 3 days after adoptive transfer of DsRed+ P14 splenocytes the 
mice were stimulated in vivo with 2 mg GP33 peptide in 900 µl H2O with 
50 µg CpG and on day six 500 µg of Poly(I:C) was administered (i.p.). 
10.2.3.3  Glucose challenge 
Mice  were  fasted  for  12-16  hours  and  than  received  a  single  intra 
peritoneal injection of 1.5 mg/g body weight glucose. Blood glucose 
was measured immediately before injection and then at 10, 20,  30, 
40, 60, 120, 240, and 450 minutes after infection. 
10.2.3.4  Liver and lung perfusions 
Liver 
Mice were anesthetized with isofluran and killed by cervical dislocation. 
After  the  abdomen  had  been  opened  the  hepatic  vein  and  hepatic 
artery were cut and the liver was perfused with ~ 5 ml PBS through   128
the hepatic portal vein. The liver was removed and appropriately stored 
for further processing. 
Lung 
Mice  were  anesthetized  with  isofluran.  After  the  abdomen  had  been 
opened the hepatic vein and hepatic artery were cut and the lung was 
perfused by injecting  ~ 5 ml PBS through the right heart chamber. The 
lung was removed and appropriately stored for further processing. 
10.2.3.5  Surgical  preparation  of  the  pancreas  for  real-time 
imaging by two-photon microscopy 
Before  surgery,  Mice  were  anesthetized with  an  appropriate  dose  of 
ketamin/xylazine. After cleaning and shaving the belly area an incision 
was made in the belly region to expose the spleen and the pancreatic 
tail region. After cauterization of the splenic arteries, the spleen was 
removed from the pancreas and the exposed pancreatic tail was fixed 
with glue on a custom-designed imaging stage and immersed in saline 
buffer. To maintain the body temperature of the mice during the whole 
image period the imaging stage was surrounded with a saline buffer 
filled basin that was continuously heated to 37°C. At the end of the 
movies an intravenous injection of 70 kDA, Texas Red-labeled dextran 
was used to visualize vascular networks. 
10.2.3.6  Alzet mini-osmotic pump implantation 
The  pumps  were  filled  with  a  CXCR3  antagonist  (NIBR2130)  and 
subcutaneous implanted in mice. After two weeks of implantation the 
pumps were changed for two weeks more. 
The  pumps  were  filled  under  sterile  conditions.  The  empty  pumps 
together with the flow moderator were weighed for the calculation of 
the solution loaded. The pumps were carefully filled with a 1 ml syringe   129
attached  a  blunt-tipped  27  gauge  filling  tube.  The  subcutaneous 
implantation  of  the  pumps  followed  the  insertion  of  the  flow 
moderation into the body of the pump. After anesthetizing the mice 
the  skin  at  the  back  slightly  posterior  to  the  capsulae  was  shaved, 
washed and a suitable incision was made. The subcutaneous tissue was 
spread to a pocket, the pump was inserted and the wound was closed 
with sutures. After implantation 1 ml 0.9% NaCl solution preheated to 
37°C  was  injected  next  to  the  pump  to  provide  movement  of  the 
pump. Either the following one to two days or every second day the 
NaCl injection was repeated.   130
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